-
Shenzhen Chipscreen Biosciences Announces Private Placement to Fund Drug R&D and Expansion
•
China-based biopharmaceutical company Shenzhen Chipscreen Biosciences Co., Ltd (SHA: 688321) has announced plans for a private placement of 122,000,000 shares, valued at RMB 960 billion (USD 133 million). This strategic move aims to bolster the company’s financial position and support its research and development (R&D) initiatives. Investment in In-House Drug…
-
LaNova Medicines Inks Licensing Deal with Sino Biopharmaceutical for Cancer Therapies in China
•
Shanghai-based LaNova Medicines Ltd, a developer of cancer therapies, has announced another licensing deal, signing an agreement with compatriot firm Sino Biopharmaceutical Ltd (HKG: 1177) for the development and commercialization of LM-108 and other potential bispecific antibodies (BsAbs) and antibody drug conjugates (ADCs) in mainland China. The specifics of the…
-
Worg Pharmaceuticals Secures Major Financing for Allergy and Autoimmune Disease Therapies
•
Worg Pharmaceuticals (Zhejiang) Co., Ltd., a China-based biopharmaceutical company specializing in the development of immunotherapies for allergic and autoimmune diseases, has successfully raised hundreds of millions of renminbi in a new financing round. The round saw participation from notable investors such as PICC Investment, Tsing Song Capital, and an undisclosed…
-
Zai Lab Ltd Announces Secondary Public Offering Worth $230 Million
•
Zai Lab Ltd (ZLAB; NASDAQ: ZLAB; HKG: 9688), a leading biopharmaceutical company, is set to raise capital through a secondary public offering of American Depositary Shares (ADSs) valued at USD 230 million. The offering consists of 7,843,137 ADSs, with each ADS representing ten ordinary shares of the company, priced at…
-
C-Ray Therapeutics Secures Over $100 Million in Series A+ Financing for Radiopharmaceuticals
•
C-Ray Therapeutics, a specialist in radiopharmaceuticals headquartered in Chengdu, has announced the successful completion of a Series A+ financing round, raising over USD 100 million. The funding was co-led by Shenzhen Capital Group’s Manufacturing Transformation and Upgrading New Materials Fund and Tailong Capital, with additional contributions from GL Ventures, 3SBio…
-
BioNTech Acquires Biotheus for $800 Million, Enhancing Oncology Pipeline
•
BioNTech (NASDAQ: BNTX), the biotech giant recognized for its role in developing the COVID-19 vaccine, has acquired Biotheus for an upfront payment of $800 million, with additional milestone payments potentially reaching up to $150 million. Founded in 2018 and headquartered in Zhuhai, China, Biotheus has developed eight clinical-stage products and…
-
C-Ray Therapeutics Secures Over $100 Million in A+ Round Financing
•
C-Ray Therapeutics (Chengdu) Co., Ltd., an innovative enterprise in the field of radioactive medicines, has successfully completed over $100 million in A+ round financing. This funding round was jointly led by Shenzhen Capital Group’s New Materials Fund and Tailong Investment, with participation from notable investors including Hillhouse Ventures, SiBiono GeneTech,…
-
Impact Therapeutics Secures $34.5 Million in Series D++ Financing for Senaparib Commercialization
•
China-based biopharmaceutical company Impact Therapeutics has reportedly secured RMB 250 million (USD 34.5 million) in a Series D++ financing round, co-led by a globally renowned industry investment institution and a prominent insurance fund. The funds raised will be directed towards the commercialization of its core product, senaparib, a PARP1 inhibitor,…
-
PegBio Files for IPO on Hong Kong Stock Exchange
•
PegBio Co., Ltd., a specialist in endocrine metabolism based in Suzhou, has taken a significant step towards going public with an initial public offering (IPO) filing to the Hong Kong Stock Exchange (HKSE). While the price and other specific details of the offering are yet to be disclosed, the move…
-
Cullgen and Pulmatrix Merge to Form Nasdaq-Listed Protein Degradation Company
•
Cullgen Inc., a clinical-stage biopharmaceutical company with operations in China, the US, and Japan, is poised to merge with US-based Pulmatrix, Inc. (NASDAQ: PULM). The merger will result in a Nasdaq-listed entity focused on advancing targeted protein degradation technology, a promising field in drug development. Cullgen’s uSMITE Technology PlatformCullgen leverages…
-
Sihuan Pharmaceutical Plans IPO for Xuanzhu Biopharm on Hong Kong Stock Exchange
•
China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has announced a renewed attempt to spin off its subsidiary, Xuanzhu Biopharmaceutical Co., Ltd (Xuanzhu Biopharm), for an initial public offering (IPO) on the Hong Kong Stock Exchange. This follows an earlier aborted effort to list on Shanghai’s Sci-Tech Innovation Board (STAR)…
-
Triton Partners Mulls Acquisition of Germany’s Evotec SE, Shares Soar 22%
•
Private equity firm Triton Partners is reportedly contemplating the acquisition of Germany-based Evotec SE (NASDAQ: EVO), as per information from Reuters. This news catalyzed a 22% surge in Evotec’s shares on Monday, reflecting market anticipation of the potential deal. Triton’s Interest and ShareholdingTriton Partners has been in the process of…
-
Leman Biotech Secures Over USD 13.9 Million in Series A Financing for Next-Gen Cancer Immunotherapies
•
China-based Leman Biotech Co., Ltd. has reportedly completed the first closing of its Series A financing round, raising over RMB 100 million (USD 13.9 million). The round was led by Fuho Capital, with additional contributions from Jun Yi Investment and AI-driven drug R&D leader XtalPi. The funds will be directed…
-
Jiangsu Kanion Pharmaceutical to Acquire Xintrum Pharmaceuticals for RMB 270 Million
•
Jiangsu Kanion Pharmaceutical Co., Ltd (SHA: 600557), a China-based pharmaceutical company, has announced its intention to acquire 100% stakes in Xintrum Pharmaceuticals, Ltd, a biologic drug developer, for a consideration of RMB 270 million (USD 37.7 million). Upon completion of the deal, Xintrum will become a wholly owned subsidiary of…
-
Nuwacell Biotechnologies Secures RMB150 Million in Series B Financing for iPSC Therapies
•
Nuwacell Biotechnologies Co., Ltd., a specialist in induced pluripotent stem cell (iPSC) technology based in Heifei, Anhui province, has reportedly secured RMB150 million (USD21 million) in the first closing of its Series B financing round. The funding was led by Guangzhou Industry Investment, with significant contributions from China Resources International,…
-
Northeast Pharmaceutical to Acquire Majority Stake in Dingcheng Peptide Source for RMB 186.8 Million
•
China-based Northeast Pharmaceutical Co., Ltd (SHE: 000597) has announced its intention to acquire a 70% stake in Beijing Dingcheng Peptide Source Biotechnology Co., Ltd, a fellow Chinese firm, for a consideration of RMB 186.8 million. This strategic move is aimed at bolstering Northeast Pharmaceutical’s presence in the cell therapy sector.…
-
Neurodawn Pharmaceutical Secures Hundreds of Millions in Series C Financing
•
Nanjing-based central nervous system (CNS) drug developer, Neurodawn Pharmaceutical Co., Ltd, has announced the successful completion of a Series C financing round, raising hundreds of millions of renminbi. The funding was led by Nanjing Jiangning High Tech Zone Science and Technology Entrepreneurship Investment Management Co., Ltd and Huaxing Kangping Pharmaceutical…
-
Innovent Biologics Halts Subscription Agreement with Lostrancos Ventures
•
China-based Innovent Biologics, Inc. (HKG: 1801) has announced the decision not to proceed with a subscription agreement between its wholly owned subsidiary, Fortvita, and Lostrancos Ventures Ltd. The agreement would have seen Lostrancos acquire a 20% stake in Fortvita for USD 20.5 million. Despite this setback, Innovent Biologics reaffirmed its…
-
Innovent’s Fortvita Stake Sale Sparks Controversy, Shares Plummet Nearly 13%
•
Innovent Biologics, Inc. (HKG: 1801), headquartered in China, has announced a subscription agreement in which its wholly owned subsidiary Fortvita will sell a 20% stake to Lostrancos Ventures Ltd. for USD 20.5 million. This news has sparked market controversy, with some investors criticizing the valuation of Fortvita as being too…
-
TheDerma’s Series A+ Round to Fund R&D and Commercialization of AhR Targeted Drugs
•
TheDerma, a Shanghai-based pharmaceutical company, has announced the completion of a nearly CNY 100 million Series A+ financing round. The round was led by Qingdao Guoxin, with existing shareholders Baino Capital, Han Kang Capital, and Beta Fund continuing to add investments. Kaicheng Capital once again served as the exclusive financial…
-
Beijing Biostar Technologies Goes Public in Hong Kong to Fund Cancer Drug Development
•
Beijing Biostar Technologies Ltd (HKG: 2563), a leading synthetic biology-driven anti-tumor drug specialist based in China, has successfully completed an initial public offering (IPO) on the Hong Kong Stock Exchange. The company issued 14,588,000 shares at a price of HKD 22 each, raising a total of HKD 320 million (USD…
-
Otsuka Holdings Weighs Sale of Stake in Medical Device Maker MicroPort Scientific
•
Otsuka Holdings Co., a Japanese pharmaceutical and healthcare company, is reportedly considering the sale of its shares in Shanghai-based medical device giant MicroPort Scientific Corp. (HKG: 0853), according to a Bloomberg report. The company is said to be working with financial advisors to assess its minority stake in MicroPort after…
-
Stem-Cell Startup Xellsmart Secures Over RMB 100 Million in Series B1 Financing for Neurological Therapies
•
Xellsmart, a stem-cell startup headquartered in Suzhou, has reportedly secured over RMB 100 million (USD 14.08 million) in a Series B1 financing round. The round was led by Tialong/Taikun Equity Investment Fund, with additional investments from Septwolves Venture Capital and Sky World Capital, alongside returning investors Frees Fund, Qiming Venture…
-
Beijing Biostar Pharmaceuticals Set to Go Public on HKEX with Focus on Oncology Innovation
•
On October 18, 2024, the Hong Kong Stock Exchange announced that Beijing Biostar Pharmaceuticals Co., Ltd. is set to go public following a successful hearing. CCB International and CITIC Securities International will serve as joint sponsors for the listing. According to the prospectus, Biostar is a biotechnology company driven by…
-
LaNova Medicines Secures RMB 300 Million in Series C1 Financing to Advance Cancer Therapy Pipeline
•
LaNova Medicines Ltd, a Shanghai-based developer of cancer therapies, has announced the successful completion of a Series C1 financing round, raising RMB 300 million (USD 42.1 million). The funding round was led by Sino Biopharmaceutical Ltd (HKG: 1177), with significant contributions from Shanghai Pudong Venture Capital, Zhangjiang Haoheng Innovative Equity…
-
TenNor Therapeutics Secures USD 42.16 Million in Series E Financing for Antibacterial Pipeline
•
TenNor Therapeutics, a clinical-stage pharmaceutical company based in China, has announced the successful completion of its Series E financing round, raising RMB 300 million (USD 42.16 million). The financing was co-led by Zhongshan Venture Capital and the AMR Action Fund. The funds raised will be directed towards the late-stage clinical…
-
iRegene Therapeutics Secures Over USD 14 Million in Series B Financing to Advance Cell Therapies
•
iRegene Therapeutics, a Wuhan-based biotechnology company specializing in the development of AI-enhanced chemically induced cell therapies, has announced the successful completion of its Series B financing round, raising over RMB 100 million (USD 14.15 million). The financing was co-led by Orinno Capital, with additional investments from Optics Valley Industrial Investment…
-
Akeso Biopharma Secures USD 250 Million in Share Placement, Bolstering Drug Development War chest
•
Akeso Biopharma (HKG: 9926), a biopharmaceutical company based in China, has declared the successful completion of a share placement that has raised USD 250 million. This capital raise has garnered significant attention from international investment firms, with a majority of the final subscribers being long-term and healthcare funds. With this…
-
Beijing Aosaikang Pharmaceuticals Boosts Stake in US Subsidiary AskGene with RMB 220 Million Investment
•
Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755) has announced a capital injection of RMB 220 million (USD 31 million) into its US-based subsidiary, AskGene Limited, established in 2012. This investment increases the Chinese firm’s shareholding in AskGene from 59.07% to 62.86%, solidifying its position as the controlling shareholder. Concurrently, TF…
-
Kailera Therapeutics Emerges with USD 400 Million in Series A Funding for Anti-Obesity Pipeline
•
Kailera Therapeutics, a newly launched US-based biotechnology company, secured USD 400 million in Series A financing last week. Previously operating as Hercules CM Newco Inc., the company was established by a consortium of investors including Bain Capital Life Sciences, RTW Investments, Atlas Venture, and Lyra Capital. The pipeline of Kailera…
-
Genor Biopharma to Acquire EOC Pharma Group in a Merger Deal, Eyeing Commercialization Synergies
•
Genor Biopharma Holdings Limited (HKG: 6998) has announced a definitive merger agreement with EOC Pharma Group (China) Co., Ltd. As part of the agreement, Genor Biopharma will acquire EOC Pharma through a share exchange, resulting in a reverse takeover. The company will change its name to “Edding Genor Group Holdings…
-
Zephyrm Biotechnologies Aims for HKEX Main Board with Innovative Cell Therapy Products
•
Zephyrm Biotechnologies Co., Ltd. (hereinafter referred to as “Zephyrm Bio”) officially submitted its prospectus to the Hong Kong Stock Exchange (HKEX) on September 30, 2024, with the intention to list on the Main Board, with CICC acting as the sole sponsor. Established in 2017, Zephyrm Bio, a clinical-stage biopharmaceutical company,…
-
Whittilong Pharma Secures Over RMB 100 Million in Series B Financing for Modified Drug Development
•
Whittilong Pharma, a Shanghai-based modified drug development company backed by Shanghai Healthcare Capital (SHC), has reportedly secured over RMB 100 million in a Series B financing round. The funding was provided by multiple family offices. Established in 2018, Whittilong Pharma specializes in the research and development of a diverse range…
-
2seventy bio and BMS Discontinue Phase III Trial for Multiple Myeloma Therapy Abecma
•
2seventy bio Inc. (NASDAQ: TSVT), a U.S.-based biotechnology company partnered with Bristol-Myers Squibb (BMS, NYSE: BMY) on the development of the chimeric antigen receptor (CAR) T-cell therapy Abecma (idecabtagene vicleucel; ide-cel), has announced the discontinuation of enrollment in a Phase III clinical trial. The trial, known as KarMMa-9, was investigating…
-
Johnson & Johnson Reportedly Winding Down Cardiovascular and Metabolic Pharma Unit
•
Johnson & Johnson (J&J; NYSE: JNJ), a healthcare giant in the U.S., is reportedly winding down its cardiovascular and metabolic pharmaceutical unit, as reported by Endpoints News. Insiders have indicated that J&J has issued notices to its sales, marketing, and medical affairs teams this week. The company has acknowledged the…
-
Suzhou’s LongBio Secures RMB 100 Million in Series B2 Financing to Advance Clinical Programs
•
LongBio, a biopharmaceutical company specializing in biomacromolecule drug development and based in Suzhou, China, has reportedly secured nearly RMB 100 million in a Series B2 financing round. The round was led by Qiming Venture Partners, with the funds earmarked to accelerate the clinical trials of its core programs in China,…
-
Apeloa Pharmaceutical Invests in Ji Xing Pharmaceuticals’ Series D Financing Round
•
China-based Apeloa Pharmaceutical Co., Ltd (SHE: 000739) has announced its participation in the Series D financing round of fellow Chinese firm Ji Xing Pharmaceuticals, contributing USD 2.75 million for a 0.58% stake in the Shanghai-based company. The investment round also saw contributions from Ji Xing’s founder, RTW Holding Limited, and…
-
Organon Inks Deal to Acquire Dermavant, Bolstering Dermatology Portfolio with Vtama Cream
•
US healthcare company Organon (NYSE: OGN) has announced a definitive agreement to acquire Dermavant, a Roivant (NASDAQ: ROIV) subsidiary focused on dermatological treatments. The acquisition is primarily driven by Dermavant’s Vtama (tapinarof) cream, a 1% topical formulation approved for plaque psoriasis and currently under regulatory review for atopic dermatitis (AD).…
-
Beijing’s MoleculeMind Secures Series A Funding to Accelerate AI Protein Design Innovations
•
MoleculeMind, a Beijing-based AI protein design platform, has reportedly secured a Series A financing round, raising hundreds of millions of renminbi. The funding was co-led by Cherami Investment and Shenzhen Capital Group, with participation from Sense Capital and EBI Investment. The capital raised will be directed towards enhancing the company’s…
-
CSA Medical Inc. Secures USD 53 Million in Series D Financing to Advance Cryotherapy Treatment
•
CSA Medical Inc., a U.S.-based medical technology company, has successfully closed a Series D financing round, securing USD 53 million in capital. This financing was co-led by TVM Capital Life Science and China-focused Yonjin Ventures, with significant participation from existing investors including SV Health Investors, Ascension Ventures, First Analysis, Blue…
-
JHM Biopharma Secures Over USD 28 Million in Series B+ Financing to Boost Pipeline Development
•
JHM Biopharma, a protein drug developer based in Hangzhou, has reportedly secured over RMB 200 million (USD 28 million) in a Series B+ financing round. This follows a Series B funding of RMB 100 million (USD 14 million) in May, bringing the total funds raised to RMB 350 million (USD…
-
Rigel Pharmaceuticals Strikes Deal with Kissei for Development and Commercialization of Rezlidhia in East Asia
•
Rigel Pharmaceuticals Inc. (NASDAQ: RIGL), a biopharmaceutical company based in the U.S., has entered into a license and supply agreement with Japan’s Kissei Pharmaceutical Co., Ltd. The agreement grants Kissei the rights to develop and commercialize Rigel’s Rezlidhia (olutasidenib) across Japan, South Korea, and Taiwan. Rezlidhia is an oral isocitrate…
-
Jiangsu Suzhou Launches $843 Million Biomedicine Fund to Boost Pharma and Medical Device Innovation
•
The Jiangsu Suzhou Biomedicine Industry Special Fund of Fund (FoF), a colossal pharmaceutical investment vehicle with a capitalization of RMB 6 billion (USD 843 million), debuted last week. This 15-year financial instrument is designed to target and catalyze growth in innovative drugs, medical R&D, medical devices, healthcare services, and synthetic…
-
CGeneTech Secures RMB 100 Million in Series C Financing to Advance Drug Commercialization and Clinical Pipeline
•
CGeneTech (Suzhou, China) Co., Ltd., a biopharmaceutical company based in China, has reportedly secured a Series C financing round totaling RMB 100 million, led by Tongren Boda Investment. The capital raised will be strategically allocated towards the commercial-scale manufacturing and marketing efforts for its flagship product, centagliptin, a Category 1…
-
Tiantan Biological to Acquire Wuhan Zhongyuan Ruide for $185 Million, Expanding Plasma Resources
•
BEIJING—Beijing Tiantan Biological Products Co., Ltd (Tiantan Biological, SHA: 600161) has announced that its subsidiary, Chengdu Rongsheng Pharmaceutical Co., Ltd (Chengdu Rongsheng), intends to acquire 100% equity interest in Wuhan Zhongyuan Ruide Biological Products Co., Ltd (Zhongyuan Ruide), a wholly-owned subsidiary of CSL Behring Asia Pacific Limited (CSL Asia Pacific),…
-
MicroPort CardioFlow to Acquire RMB 380 Million Shanghai Assets for Global HQ Expansion
•
China-based MicroPort Scientific Corp. (HKG: 0853) has announced that its spin-off, MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), will acquire a 100% stake in Shanghai Heart Forever Medical Technology Co., Ltd. The acquisition, valued at up to RMB 380 million, will be executed through a transfer from its sister company,…
-
Leaderna Therapeutics Secures RMB 100 Million in Funding to Accelerate Nucleic Acid Drug Development
•
CHENGDU—Leaderna Therapeutics Ltd, a pioneering nucleic acid drug developer, has reportedly secured nearly RMB 100 million in a recent financing round spearheaded by Hygeia Capital. The syndicate of investors includes CAS STAR, Chengdu Biocity Jingchuang Equity Investment Fund, CS Ventures, and other prominent firms. The newly raised capital is earmarked…
-
China’s WORK Medical Technology Targets U.S. Market with Upcoming IPO
•
China-based WORK Medical Technology Group Ltd has priced its initial public offering (IPO) at USD per share for a total of 2,000,000 ordinary shares. The shares have received approval for listing on the Nasdaq Capital Market and are set to begin trading on August 23, 2024, under the ticker symbol…
-
UCB Agrees to USD 680 Million Divestment of China Neurology and Allergy Business to CBC Group and Mubadala
•
UCB, a Belgium-based biopharmaceutical company listed on the Brussels Stock Exchange (FRA: UNC), has announced the signing of a definitive agreement to divest its established neurology and allergy business in China. The transaction involves the sale to two prominent investment firms, the Singapore-based CBC Group and the Abu Dhabi-based Mubadala,…
-
Suzhou-Based Medical Device Innovator Ensurge Secures RMB 100 Million in Latest Financing Round
•
Ensurge, a cutting-edge medical device manufacturer headquartered in Suzhou, is reportedly in the spotlight for securing a new round of financing that has yielded RMB 100 million. The funding round saw participation from a consortium of investors including TPIC, Legend Capital, and Peakview Capital. The capital raised is earmarked for…
-
Bone Index Secures Financing to Expand Manufacturing and Promote Diagnostic Technology Globally
•
Bone Index, a Finland-based medical technology company specializing in bone diagnostics, has announced the successful completion of a new financing round, with the exact amount remaining undisclosed. The round was spearheaded by Lynx Financial, a Shanghai-based fund with a dedicated focus on healthcare and life sciences, and was supported by…
-
Finland’s Bone Index Partners with Lynx Financial for APAC and North American Market Expansion
•
HELSINKI—Bone Index, a pioneering medical technology company headquartered in Finland, has announced the successful completion of a new financing round, with the exact amount remaining undisclosed. The round was led by Shanghai-based Lynx Financial, a fund with a dedicated focus on healthcare and life sciences, and was supported by contributions…
-
Shineyo Medical Secures RMB 100 Million in Series A+ Funding for Cardiac and Vascular Devices
•
Shineyo Medical, a Shanghai-based manufacturer of electrophysiological and peripheral interventional devices, has reportedly secured nearly RMB 100 million (USD 13.9 million) in a Series A+ financing round. The funding was spearheaded by Guangzhou Jinkong Fund, with additional investments from Zhuopu Investment fund, Jinxin Capital, and Zhangjiagang Industrial Capital, along with…
-
Hygeia Healthcare Holdings Acquires Chang An Hospital in Deal Valued at RMB 1.66 Billion
•
Hygeia Healthcare Holdings Co., Ltd, a Shanghai-based medical investment and healthcare group, has announced the completion of an acquisition, securing a 100% stake in Chang An Hospital, a state-owned Class 3A general hospital. The transaction, which is reported to have already been finalized, involved a consideration of approximately RMB 1.66…
-
Eisai and SEED Therapeutics Join Forces on Molecular Glue Degraders for Neurodegeneration and Cancer
•
Eisai Co., Ltd (TYO: 4523), a Japanese pharmaceutical company, and SEED Therapeutics Inc., a U.S. biotech firm, have announced their intention to enter into a research collaboration aimed at developing novel molecular glue degraders for neurodegenerative diseases and oncology. Eisai will leverage SEED’s expertise in targeted protein degradation (TPD) to…
-
Shanghai Aims to Become Capital Market Hub for High-Quality Science and Innovation Companies
•
The Shanghai municipal government has unveiled a comprehensive set of measures designed to enhance the city’s capital market’s role in fostering the high-quality development of science and innovation companies. The strategic initiative aims to establish Shanghai as a premier investment and financing hub for new quality productivity, a showcase for…
-
Shenzhen-Based Synthetica Secures Initial Funding to Advance Oncolytic Bacteria Pipeline
•
Synthetica, a pioneering developer of live bacteria drugs based in Shenzhen, has announced the successful completion of its first round of financing, with the specific amount remaining undisclosed. The round was led by Boehringer Ingelheim Venture Fund and Temasek, with participation from Lenovo Capital and Incubator Group, Fosun Health, and…
-
Suzhou Hanerxi Medical Secures Series B Funding to Build Asia’s Largest Pen Injector Facility
•
Suzhou Hanerxi Medical Device Development Co., Ltd, a specialist in pen syringe technology based in Suzhou, has reportedly secured “hundreds of millions” of renminbi in a Series B financing round. The round was led by Fuzhe Equity Investment Fund and Jiangsu Trautec Medical Technology Co., Ltd., with additional contributions from…
-
GSK Enters into Strategic Partnership with Flagship Pioneering to Develop Novel Medicines and Vaccines
•
UK pharmaceutical giant GlaxoSmithKline (GSK; NYSE: GSK, LON: GSK) has announced a new partnership with Flagship Pioneering, a biotech company based in Cambridge, Massachusetts, known for its role as a bioplatform for innovation across a diverse portfolio of over 40 companies. The collaboration will see an initial joint funding of…
-
Livzon Pharmaceutical Group to Establish Joint Venture with PT Kalbe Farma in Indonesia
•
China-based Livzon Pharmaceutical Group Inc. (HKG: 1513) has announced plans to form a joint venture (JV) with Indonesia’s leading pharmaceutical company, PT Kalbe Farma, TBK. The JV, with a registered capital valued at approximately RMB 582 million, will focus on the manufacturing of active pharmaceutical ingredients (APIs) in Southeast Asia.…
-
LTZ Therapeutics Secures Over USD 20 Million in Series A Financing to Advance Immunotherapy Pipeline
•
LTZ Therapeutics Inc., a biotechnology company specializing in immunotherapy with operations in both the US and China, has reportedly raised more than USD 20 million in a Series A financing round. The funding round was led by Lapam Capital, with participation from GL Ventures as well as existing investors Qiming…
-
Guangzhou Red Pine Medical Secures Series D Funding to Accelerate Global Expansion
•
Guangzhou Red Pine Medical Instrument Co., Ltd., a leading company in the disposable endoscope sector, has reportedly secured “hundreds of millions” of renminbi in a Series D financing round. The round was led by CICC Capital, with significant contributions from Guangzhou Industrial Investment and Capital, Oriza Seed, and other investors.…
-
Bristol-Myers Squibb Q2 2024 Sales Boosted by Growth Portfolio, Offset by R&D Impairment
•
Bristol-Myers Squibb (BMS; NYSE: BMY) has announced its financial results for the second quarter of 2024, with global sales increasing by 11% year-on-year to $12.2 billion, based on constant exchange rates. The growth was driven in part by the company’s ‘growth portfolio,’ which includes a dozen newer drugs that saw…
-
Shanghai’s Spectrum Dynamics Medical Secures Major Financing for Molecular Imaging Innovations
•
Spectrum Dynamics Medical, a Shanghai-based specialist in medical molecular imaging, has reportedly secured hundreds of millions of renminbi in a new financing round. The round was led by Shanghai Healthcare Capital (SHC), a prominent municipal industry fund in Shanghai, with the participation of Oriental Fortune Capital. This funding round is…
-
AstraZeneca’s Q2 2024 Results Highlight Strong Growth Across Therapies, Excluding Vaccines
•
AstraZeneca (NASDAQ: AZN), a UK-based biopharmaceutical company, has reported its financial results for the second quarter and the first half of 2024, demonstrating robust growth. For the six-month period, total revenues increased by 18% year-on-year (YOY) to $25.617 billion, with product sales also experiencing an 18% rise to $24.629 billion.…
-
RemeGen Scales Back Private Placement to Fund New Drug R&D
•
RemeGen (HKG: 9995), a biopharmaceutical company based in China, has revised its private placement plan, reducing the funds raised from the initially disclosed RMB 2.55 billion in June to RMB 1.953 billion. The capital will be directed towards the research and development of new drugs, bolstering the company’s pipeline which…
-
Shanghai Desano and Chongqing Kangfude Partner to Establish Peptide Drug Production Base in China
•
Shanghai Desano Biopharmaceutical Co., Ltd, a leading biopharmaceutical company based in China, has entered into a strategic partnership with Chongqing Kangfude Pharmaceutical Co., Ltd to establish a state-of-the-art peptide drug API and preparation production base in Chongqing. The collaboration involves an investment of RMB 120 million (USD 16.5 million) by…
-
Fosun Pharma and Kite Pharma Inject USD 28.5 Million into Joint Venture for CAR-T Therapy Development
•
Shanghai Fosun Pharmaceutical Group Co., Ltd (SHA: 600196; HKG: 2196) and Kite Pharma, a subsidiary of Gilead, have announced plans to bolster their joint venture, Fosun Kite Biotechnology Co., Ltd, through a capital increase. This will be achieved by proportionally converting their existing debt into equity, amounting to USD 28.5…
-
MicroPort CardioFlow Secures Exclusive Distribution Rights for Evermend Occluders in China
•
MicroPort Scientific Corp (HKG: 0853), a leading medical device company based in China, has announced that its spin-off, MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), has entered into a distribution framework agreement with Dongguan Kewei Medical Instrument Co., Ltd. Kewei, which was acquired by MicroPort Scientific in 2012, has agreed…
-
Rona Therapeutics Secures USD 35 Million in Series A+ Round to Advance Nucleic Acid Therapies
•
Rona Therapeutics, a Shanghai-based nucleic acid drug developer, has secured USD 35 million in a Series A+ financing round led by LongRiver Investments. The funding round also saw participation from Zhaode Investment, Zhongqi Capital, BioTrack Capital, and Lilly Asia Ventures. The company plans to utilize the proceeds to accelerate its…
-
Beijing X-Magtech Secures Over RMB 100 Million in Series A+ Funding for Magnetic Field Measurement Tech
•
Beijing X-Magtech Technologies, a specialist in ultra-weak magnetic field measurement technology, has reportedly secured over RMB 100 million (USD 13.8 million) in a Series A+ financing round. The funding round was led by the Beijing Robot Industry Development Investment Fund, with participation from CAS Star and existing investors including Everest…
-
Guotai Junan and Haitong Securities to Launch $10 Billion in Industry Funds in Shanghai
•
China’s prominent financial institutions, Guotai Junan Securities and Haitong Securities, have revealed plans to establish three industry-focused funds of funds (FoFs) in Shanghai with a combined target pool of RMB 89 billion (approximately USD 13.1 billion). These funds, to be managed by a newly formed entity, Shanghai Guotou Pioneer Private…
-
E-Health Now Secures USD 13.8 Million in Series C Financing to Expand AI Medical Services
•
E-Health Now, a China-based one-stop artificial intelligence (AI)-powered medical health service platform, has reportedly secured nearly RMB 100 million (USD 13.8 million) in a Series C financing round. The funding round attracted notable investors such as Ameba Capital, Ventech China, and Borchid Capital. The capital raised is intended to fuel…
-
AusperBio Secures $37 Million in Series A Funding to Advance Hepatitis B Therapy AHB-137
•
AusperBio, a sino-American biotechnology company specializing in liver therapy development, has reportedly secured USD 37 million in a Series A financing round. The round was spearheaded by the InnoPinnacle Fund, with additional investments from a consortium that includes Yuanbio Venture Capital, Hankang Capital, Qiming Venture Partners, and Genesis Capital. The…
-
Legend Biotech’s Shares Leap on Acquisition Rumors; Parent Genscript Biotech Corp. Follows Suit
•
Chinese biopharmaceutical firm Legend Biotech (NASDAQ: LEGN), a specialist in chimeric antigen receptor (CAR) T-cell therapy, has reportedly drawn the attention of a potential acquirer. This development sent Legend’s stock price climbing over 12% in a single day, as reported by the news platform Street Insider. The company has allegedly…
-
Abbisko Therapeutics Forecasts Profits and Revenue Boost in H1 2024 on Merck Deal
•
Abbisko Therapeutics Co., Ltd (HKG: 2256), a Shanghai-based biotechnology company, has released a positive financial forecast for the first half of 2024. The company anticipates total revenues to amount to RMB 497 million (USD 68.34 million) over the six-month period, marking a significant uptick. Additionally, Abbisko expects to report its…
-
Xinzeyuan Medical Technology Secures Over RMB 100 Million in Series B Financing
•
Xinzeyuan Medical Technology Co., Ltd, a Hangzhou-based micro invasive medical device supply chain platform, has reportedly secured over RMB 100 million (USD 13.8 million) in a Series B financing round. The round was led by Qiming Venture Partners, with Silicon Paradise also participating in the funding. The company plans to…
-
Singlera Genomics Secures Over RMB 100 Million in Strategic Financing to Boost R&D and Commercialization
•
Singlera Genomics Inc., a genetic testing and molecular diagnostics company with operations in San Diego, California, and in Shanghai and Yangzhou, China, has reportedly secured over RMB 100 million in a strategic financing round. The funding was led by Yangzhou Guojin, Longchuan Holding, and other municipal state-owned funds based in…
-
Chengdu-Based Vaccine Specialist Maxvax Biotechnology Raises USD 41.3 Million in Latest Funding Round
•
Maxvax Biotechnology, a leading vaccine-focused biotech company headquartered in Chengdu, has successfully closed its Series C+ financing round, securing over RMB 300 million (USD 41.3 million). This latest funding round was spearheaded by IDG Capital, with significant participation from Hankang Capital and Qianhai Ark Asset Management. The capital raised in…
-
Moon Biotech Secures Exclusive State-Owned Fund Investment in Series C+ Round
•
Moon (Guangzhou) Biotech Co., Ltd, a leading microbiome platform company based in China, has reportedly secured RMB 300 million (USD 41.3 million) in a Series C+ financing round. The funding was exclusively provided by SDIC JULI Investment, a state-owned investment fund. Established in 2015, Moon is recognized for possessing the…
-
TowardPi Medical Secures RMB 200 Million in Series D Financing Led by Matrix Partners
•
TowardPi (Beijing) Medical Technology Ltd, a Chinese medical technology company, has reportedly secured RMB 200 million in a Series D financing round. The round was led by Matrix Partners, with participation from GTJA Investment and other investors. Established in 2017, TowardPi Medical’s core technical team comprises numerous graduates from Tsinghua…
-
Shanghai’s Phrontline Biopharma Secures Over RMB 100 Million in Pre-Series A Funding for ADC Development
•
Shanghai-based antibody drug conjugate (ADC) specialist Phrontline Biopharma has reportedly secured over RMB 100 million (USD 13.8 million) in a pre-Series A financing round, with funds exclusively provided by Decheng Capital. The capital raised will be directed towards bolstering research and development efforts, pre-clinical development, and the enhancement of its…
-
Aidea Pharmaceutical to Boost Stake in Nanda Pharmaceutical to 51.1256%
•
Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488), a pharmaceutical company based in China, is poised to acquire a 31.161% stake in fellow Chinese firm Nanjing Nanda Pharmaceutical Co., Ltd for a consideration of RMB 149.57 million (USD 20.6 million). Aidea had previously secured a 19.9646% stake in Nanda Pharma in…
-
Jiangsu Jibeier Pharm Completes Private Placement to Fund R&D Center on STAR Market
•
Jiangsu Jibeier Pharm Co., Ltd (SHA: 688566), a Chinese pharmaceutical company, has announced the successful completion of a private placement of 7,446,889 shares at a price of RMB 26.61 per share. The shares will be listed on the Science and Technology Innovation Board (STAR), which is hosted by the Shanghai…
-
Fosun Pharma to Take Henlius Private in Deal Valued at HKD 5.407 Billion
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced plans to take its subsidiary Shanghai Henlius Biotech Co., Ltd (HKG: 2696) private. According to a stock exchange announcement from the China-based firm, Fosun currently holds 323.7 million shares of Henlius, representing 59.56% of the company’s total shares.…
-
AnDiConBio Secures Over RMB 200 Million in Series A Financing to Advance Respiratory and Pain Therapies
•
AnDiConBio, a Zhejiang-based innovative pharmaceutical company specializing in respiratory infections and pain management, has reportedly secured over RMB 200 million in a Series A financing round. The round was led by Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096), Huajin Investment, and Huajin Dadao Investment, with participation from Cowin Capital, Wenzhou…
-
METiS Therapeutics Secures USD 100 Million in Series C Financing to Advance AI Drug Delivery
•
METiS Therapeutics, a biopharmaceutical company based in Cambridge, Massachusetts, has secured USD 100 million in a Series C financing round. The round was led by CICC Capital, with additional investment from China Taiping Insurance. This latest funding round brings the total capital raised by the Sino-US firm to USD 300…
-
Ascentage Pharma’s THDBH120 Receives NMPA Approval for Phase Ib Clinical Trial
•
Ascentage Pharma (HKG: 6855), a biopharmaceutical company based in China, has announced that it has received approval from the National Medical Products Administration (NMPA) for its Phase Ib clinical study of GLP-1/GIP dual-targeted receptor agonist THDBH120 as a hypoglycemic therapy. THDBH120, which is being developed to treat type 2 diabetes…
-
DK Medical Technology Secures ‘Hundreds of Millions’ in Series E Financing for Expansion
•
DK Medical Technology Co. Ltd., a Suzhou-based developer of vascular intervention balloon products, has reportedly secured “hundreds of millions” of renminbi in a Series E financing round. The round was co-led by Legend Capital and Qiming Venture Partners, with additional investments from existing shareholders. The funds will be utilized to…
-
Shanghai Fosun Pharmaceutical Sells Stake in Gland Pharma for USD 211 Million
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced the sale of a 6.01% stake in its India-based subsidiary, Gland Pharma Ltd (BOM: 543245), through bulk trading. The transaction raised INR 7.541 billion (USD 90 million) pre-tax, or approximately USD 211 million pre-tax. Following the completion of…
-
Grifols Completes Sale of 20% Stake in Shanghai RAAS to Haier Group for RMB 12.5 Billion
•
Grifols AS (NASDAQ: GRFS), a Spain-based global leader in the production of blood products, has announced the completion of a significant transaction where it sold a 20% stake in Shanghai RAAS Blood Products Co., Ltd (SHE: 002252) to Haier Group, a Chinese electronics and appliances conglomerate, for RMB 12.5 billion…
-
3SBio Secures Long-Term Financing from IFC for Manufacturing and Global Expansion
•
3SBio Inc. (HKG: 1530), a biopharmaceutical company based in China, is slated to receive long-term loan credit from the International Finance Corporation (IFC), with the funds designated for the construction of manufacturing facilities and the development of overseas business. This development signifies that 3SBio, the first Chinese biopharmaceutical enterprise to…
-
CATUG Biotechnology Secures Nearly RMB 100 Million in Latest Financing Round to Expand Globally
•
CATUG Biotechnology, a cutting-edge company in the nucleic acid and gene therapy sector, has announced the successful completion of a new financing round, raising nearly RMB 100 million (USD 13.8 million). This funding round was led by prominent investors Yifeng Capital and Zhiyi Investment, with additional participation from Yuanhe Holdings…
-
Neusoft IntelliRay Secures Over RMB 100 Million in Series C Funding Round
•
Neusoft IntelliRay Technology Co., Ltd, a medical technology company based in Shenyang, has successfully closed a Series C funding round, securing over RMB 100 million (approximately USD 13.8 million). The financing was spearheaded by Leli PE Capital and Neusoft Capital, with the funds earmarked for the advancement and market expansion…
-
Ronovo Surgical Secures Over RMB 300 Million in Series B to Globalize Surgical Robot
•
Shanghai-based surgical robotics specialist, Ronovo Surgical, has reportedly raised over RMB 300 million (USD 41.3 million) in a Series B financing round. The funding round was co-led by Guolian Group and Ince Capital, with contributions from King Star Med LP and existing investor LongRiver. The capital will be utilized to…
-
Cellbri Bio Secures Nearly RMB 200 Million in Series B Financing to Boost CGT Commercialization
•
Shenzhen Cellbri Bio-Innovation Technology Co., Ltd, a prominent player in China’s cell and gene therapy (CGT) sector, has reportedly secured nearly RMB 200 million in a Series B financing round. The round was led by 3E Bioventures, with participation from HongSheng Capital and existing investors including Beijing Shuimu Guoding Investment,…
-
BOE-Backed Genewise Bio Secures RMB 100 Million in Series A Financing for Molecular Diagnostics
•
Genewise Bio, a molecular diagnostics company nurtured by BOE Technology Group, has reportedly secured RMB 100 million in a Series A financing round. Tsing Song Capital led the investment round, with additional investments from Wuhe Capital, Aeonmed, and Pinnacles Medtech. Established in 2021, Genewise Bio has developed a comprehensive independent…
-
Lucy Therapeutics Boosts CNS Disease Research with USD 12.5 Million in Additional Financing
•
Lucy Therapeutics Inc., a U.S.-based developer of small-molecule drugs for central nervous system (CNS) diseases, has raised an additional USD 12.5 million in financing. The company is jointly incubated by China-based Contract Research Organization (CRO) VIVA Biotech Holdings (HKG: 1873). Existing investors Engine Ventures and Safar Partners spearheaded the funding…
-
Fosun Pharma Rumored to Fully Acquire Subsidiary Henlius Pharmaceutical, Shares Suspended
•
Rumors are circulating, as reported by Bloomberg citing insiders, that Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) is planning to fully acquire its subsidiary Shanghai Henlius Biotech Co., Ltd (HKG: 2696). This strategic move comes as Henlius, a Hong Kong-listed company, has suspended its shares from trading…
-
IVD Medical Holding Ltd Enters Non-Binding MoU with Chinese Chemiluminescence IVD Company for Potential Collaboration
•
IVD Medical Holding Ltd (HKG: 1931), a leading in vitro diagnostic (IVD) company based in China, has announced the signing of a non-binding Memorandum of Understanding (MoU) with a fellow Chinese IVD company, which is yet to be named. The MoU outlines the intention to explore potential collaboration opportunities, including…
-
Bayer’s Consumer Health Division to Invest $83 Million in New Supply Center in China
•
Bayer (ETR: BAYN)’s Consumer Health Division has entered into an agreement with Qidong city in Jiangsu province to establish a new supply center. The German multinational pharmaceutical company will invest RMB 600 million (USD 83 million) in the initial phase of the project, with the facility expected to become operational…
-
Beijing’s Cipher Gene Secures RMB 100 Million in Series C Financing to Expand Precision Medicine Services
•
Cipher Gene, a Beijing-based gene big data and precision medicine service provider, has reportedly secured RMB 100 million in a Series C financing round. The funding round was led by Chengdu Jinjiang, with participation from Zhongxi Fund and several existing investors. The capital raised will be utilized to enhance the…
-
Blue Sail Medical Subsidiary Secures RMB 100 Million Investment to Expand Operations
•
China’s Blue Sail Medical Co., Ltd (SHE: 002382) has announced that Blue Sail Biosensors Medical Technology, its wholly-owned subsidiary, has introduced a strategic investor, Beijing Daxing Airport Economic Zone Development Fund. The fund has made a substantial investment of RMB 100 million (USD 14 million) in the company. The proceeds…
-
Pharmaron and AstraZeneca Enter Sweeping Partnership to Span Drug Development Services
•
Pharmaron Beijing Co., Ltd, a leading Contract Research Organization (CRO) based in Beijing (HKG: 3759; SHE: 300759), has announced a comprehensive strategic partnership with the UK pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN). This collaboration will encompass the entire spectrum of drug development, including small molecules, macromolecules, and gene therapies, from…
-
Pharmaron to Sell Proteologix Stake in Upcoming Johnson & Johnson Acquisition
•
Pharmaron Beijing Co., Ltd, a leading Contract Research Organization (CRO) based in Beijing (HKG: 3759; SHE: 300759), has announced the sale of its 10.21% stake in Proteologix, a US-based specialist in immune-mediated diseases. The acquisition of Proteologix is set to be completed by healthcare giant Johnson & Johnson (J&J; NYSE:…
-
Zhejiang Huahai Pharmaceutical Co., Ltd Plans Capital Raise for Digital Manufacturing Expansion
•
Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521), a leading Chinese pharmaceutical company, has unveiled plans for a private placement of 148,000,000 shares, raising a total of RMB 1.21 billion (approximately USD 170 million). The capital raised from this private placement is earmarked for the construction of digital intelligent manufacturing facilities…
-
GE HealthCare Partners with Shanghai Pudong for USD 52.5 Million Medical Tech Investment
•
GE HealthCare (NASDAQ: GEHC), a leading medical technology firm, has entered into a cooperation intent letter with the Pudong district of Shanghai, committing an investment of RMB 380 million (USD 52.5 million). This strategic partnership will focus on the introduction of new products, construction of new production lines, green factory…
-
Vision Medicals Raises Hundreds of Millions in Series D+ Round to Advance Molecular Diagnostics
•
Guangdong-based Vision Medicals has reportedly secured hundreds of millions of renminbi in a Series D+ financing round, led by Kequan Investment with participation from Tianxin Fund. The funds raised will be directed towards accelerating the research and development of precision diagnosis products focused on pathogenic molecules. Additionally, the company plans…
-
Nabla Bio Forges Partnerships with Top Pharma Companies to Tackle Challenging Drug Targets
•
Protein design specialist Nabla Bio has announced strategic collaborations with pharmaceutical giants AstraZeneca (AZ; NASDAQ: AZN), Bristol Myers Squibb (BMS; NYSE: BMY), and Takeda (NYSE: TAK). These partnerships underscore the biotech company’s commitment to leveraging its integrated AI and wet-lab technologies for the design of conformation- and target-selective antibody candidates.…
-
Elite (Suzhou) Analytical Instruments Boosts Liquid Chromatography Push with Series A+ Round
•
China-based Elite (Suzhou) Analytical Instruments Co., Ltd, a premier manufacturer of liquid chromatography devices in the nation, has reportedly secured nearly RMB 100 million (USD 13.8 million) in a Series A+ financing round. The funding round was co-led by GT (Shanghai) Equity Investment Fund and Guotai Junan Innovation Investment, with…
-
Bayer’s Q1 2024 Report Shows Slight Dip in Sales Amid Pharmaceutical Unit’s Growth
•
Germany-based Bayer (ETR: BAYN) has released its financial report for the first quarter of 2024, showing a slight 0.6% year-on-year (YOY) decrease in group sales to EUR 13.8 billion (USD 14.9 billion), excluding portfolio and exchange rate effects. The pharmaceuticals business segment reported a 3.9% increase in sales, reaching EUR…
-
Novo Nordisk’s Bispecific Antibody Mim8 Achieves Milestone in Haemophilia A Trial
•
Novo Nordisk (CPH: NOVO-B), a pharmaceutical company based in Denmark, has announced that its bispecific antibody (BsAb) Mim8 has successfully met the primary endpoints in a late-stage trial for haemophilia A. The trial focused on the reduction of treated bleeding episodes, with once-weekly and once-monthly doses of Mim8 showing reductions…
-
Healingovation Raises Over RMB 60 Million in Pre-Series A++ Round for Aquablation Surgical Robot
•
Healingovation, a Beijing-based innovator in surgical robots and intelligent diagnostic and therapeutic equipment, has reportedly secured more than RMB 60 million (USD 8.3 million) in a pre-Series A++ financing round. The round was led by CD Capital, with participation from Legend STAR, and returning investors Shunwei Capital, Lilly Asia Ventures,…
-
Subtle Medical Inc Closes USD 10 Million Series B+ Round to Accelerate Global Expansion
•
Subtle Medical Inc, a medical imaging specialist and Stanford University spin-off, has reportedly raised close to USD 10 million in a Series B+ financing round. The financing was backed by investors including Shanghai-based Wenzhou Capital, Fusion Fund, ENVISIONX Capital, Bluerun Ventures, and other strategic partners across the Asia Pacific region.…
-
DSciLab, mRNA Pharma Startup, Bags RMB 100 Million in Angel Financing Led by Fosun Health
•
DSciLab Co., Ltd, a China-based mRNA pharmaceutical company nurtured by Fosun Health Capital, has announced the completion of an angel financing round worth RMB 100 million. The round was led by Fosun Health Capital, with participation from Shanghai Creation Investment. The funds will be directed towards the advancement of core…
-
Viatris Q1 2024 Results Show Slight Dip in Base Business Brands Amid Overall Stabilization
•
US pharmaceutical company Viatris (NASDAQ: VTRS) has reported its financial results for the first quarter of 2024, with global net sales remaining flat year-on-year (YOY) at USD 3.7 billion in constant currency terms. The base business brands experienced a 2% YOY decline to USD 2.3 billion, attributed to unfavorable channel…
-
Takeda’s Fiscal 2023 Revenues Grow 1.5%, CEO Weber Forecasts 2025 Profitability After 2024 Dip
•
Takeda’s (TYO: 4502) annual report for the fiscal year ended March 31, 2024, has been released, showing a 1.5% year-on-year increase in global revenues at constant exchange rates (CER), reaching JPY 4.3 trillion (USD 27.4 billion). This growth was achieved despite a significant impact from the loss of exclusivity on…
-
Sandoz Q1 2024 Results Highlight 6% Growth, Led by Biosimilars and European Strength
•
Switzerland-based Sandoz (SWX: SDZ) has reported its financial results for the first quarter of 2024, announcing sales of USD 2.5 billion, marking a 6% year-on-year (YOY) increase in constant currency terms. This growth was driven by contributions from all regions. Generics sales experienced a modest 1% YOY increase to USD…
-
Novo Nordisk’s Q1 2024 Global Sales Surge 24% YOY on Strength of GLP-1 Therapies
•
Denmark-based pharmaceutical giant Novo Nordisk (CPH: NOVO-B) reported a substantial 24% year-on-year (YOY) increase in global sales for the first quarter of 2024, reaching DKK 65.3 billion (USD 9.4 billion) at constant exchange rates (CER). The growth was primarily attributed to strong performances in glucagon-like peptide-1 (GLP-1)-based drugs and obesity…
-
Organon’s Q1 2024 Revenues Rise 7% YOY, Women’s Health and Biosimilars Lead the Way
•
Organon (NYSE: OGN), a leading women’s health specialist, announced a 7% year-on-year increase in revenues for the first quarter of 2024, reaching $1.6 billion, excluding the impact of foreign exchange. This growth was primarily fueled by a robust performance in Women’s Health and Biosimilars segments, which saw revenues surge 12%…
-
Siemens Healthineers Reports 3% YOY Growth in Q2 2024 Fiscal Report Amidst Challenging Comparison
•
Germany’s medical technology leader Siemens Healthineers AG (ETR: SHL) has reported its financial results for the second quarter of fiscal 2024, which concluded on March 31, 2024. The company achieved total revenues of EUR 5.44 billion (USD 5.85 billion), marking a growth of 3% year-on-year (YOY) at constant currency. Siemens…
-
MSD Reports USD 15.8 Billion in Q1 2024 Sales, Marked by 11% YOY Growth Excluding Forex Impact
•
Merck, Sharp & Dohme (MSD; NYSE: MRK) has released its financial report for the first quarter of 2024, announcing sales of USD 15.8 billion, an increase of 11% year-on-year (YOY) excluding the impact of foreign exchange rates. The pharmaceutical division contributed USD 14.0 billion to the top line, with a…
-
Yantai Lannacheng Biotech Secures RMB 300 Million in Series B+ Financing Round
•
Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675) has announced that its controlling subsidiary, Yantai Lannacheng Biotechnology Co., Ltd., has successfully raised RMB 300 million (USD 41.4 million) in a Series B+ financing round. The funding round was led by Shenzhen Capital Group, with participation from Qianhai Ark Asset Management…
-
Roche’s Q1 2024 Turnover Rises 2% YOY, Driven by New Medicines and Diagnostics
•
Swiss pharmaceutical and diagnostics giant Roche (SWX: ROG) has reported a 2% year-on-year (YOY) increase in turnover at constant exchange rates (CER) for the first quarter of 2024, reaching CHF 14.4 billion (USD 15.7 billion). The growth was modest but steady, driven by newer medicines and diagnostics, which compensated for…
-
China’s CSRC Unveils 16 Measures to Boost Capital Market and Tech Enterprises
•
The China Securities Regulatory Commission (CSRC) has introduced a comprehensive set of 16 measures aimed at enhancing the capital market’s functionality, optimizing resource allocation, and bolstering the high-level development of technology enterprises.
-
Novartis Reports 11% YOY Sales Growth in Q1 2024, Led by Entresto and Cosentyx
•
Swiss pharmaceutical giant Novartis (NYSE: NVS) has reported an 11% year-on-year (YOY) increase in constant currency terms during the first quarter of 2024, reaching USD 11.8 billion in sales. The growth was driven by strong performances across all key brands and geographies. The top-selling and growth-driving drugs included hypertension therapy…
-
Impact Therapeutics Boosts War Chest with $55.2 Million Series D+ Round for Cancer Drugs
•
Impact Therapeutics, a biopharmaceutical company based in China, has reportedly secured RMB 400 million (USD 55.2 million) in a Series D+ financing round. The round was co-led by GTJA Investment and KingRay Capital, a state-owned investor focused on small and micro enterprises. Additional participants in the financing round included Guojin…
-
Abbott Reports Q1 2024 Organic Sales Growth of 4.7%, Led by Pharmaceuticals and Devices
•
Abbott (NYSE: ABT), a global healthcare giant, has this week announced its financial results for the first quarter of 2024. The company reported a 4.7% year-on-year (YOY) increase in global sales on an organic basis, reaching USD 10.0 billion. Excluding the impact of reduced demand for SARS-CoV-2 tests, the growth…
-
Boehringer Ingelheim Surpasses Bayer in Pharma Sales with EUR 20.8 Billion in 2023
•
Boehringer Ingelheim, a major German pharmaceutical company, has released its financial report for 2023, announcing human pharma sales of EUR 20.8 billion (USD 22.1 billion), marking a 10.3% year-on-year (YOY) increase, excluding currency effects. Additionally, animal health sales rose by 6.9% YOY to EUR 4.7 billion (USD 4.9 billion), leading…
-
J&J’s Medical Technology Sector Rises 6.3% YOY Despite China’s VBP Impact
•
Johnson & Johnson (J&J; NYSE: JNJ) has reported its financial results for the first quarter of 2024, announcing global sales of USD 21.4 billion, marking a 3.9% year-on-year (YOY) increase in operational terms. Both business segments performed well, with innovative medicines seeing a 2.5% YOY rise to USD 13.6 billion.…
-
LargeV Instrument’s IPO on STAR Board Halted Following Filing and Sponsorship Withdrawal
•
The initial public offering (IPO) of LargeV Instrument Corp., Ltd to the Shanghai Stock Exchange’s Sci-Tech Innovation Board (STAR) has been suspended for review, following the withdrawal of the filing and sponsorship. The Beijing-based company, which specializes in the research and development (R&D), manufacturing, and marketing of medical cone-shaped beam…
-
Genesis MedTech Secures Hundreds of Millions in Funding to Boost R&D and Manufacturing in China
•
Singapore-based medical device company Genesis MedTech has raised “hundreds of millions” of renminbi in a recent financing round co-led by Wuxi Capital Group and Wuxi Binhu Industrial Investment and Development, alongside a prominent U.S. medical device firm. The funding will support product research and development at its Wuxi facility, as…
-
Suzhou SmartNuclide Biopharmaceutical Secures $13.8 Million in Series C+ Funding to Advance Radiopharmaceutical Pipeline
•
Suzhou SmartNuclide Biopharmaceutical Co., Ltd, a leading developer of radiopharmaceuticals in China, has announced the completion of a Series C+ financing round worth RMB 100 million ($13.8 million). The round was led by Oriza Holdings, with significant contributions from YZ Capital, JianSu Capital, Leader Venture Capital, and returning investor RealHarmony…
-
Arnatar Therapeutics Secures $50 Million in Series A Funding to Expand into China
•
US-based biotechnology company Arnatar Therapeutics has successfully closed a $50 million Series A financing round, marking a significant step in the firm’s expansion plans into the Chinese market. The funding round, co-led by 3E Bioventures and Eight Roads, attracted substantial Chinese investment, highlighting the growing interest in innovative biotech solutions…
-
Applied Protein Technology Secures Series C Financing to Accelerate Multi-Omics Innovation
•
Shanghai-based Applied Protein Technology (APTBIO), a pioneer in life science technology services driven by mass spectrometry and multi-omics, has successfully raised hundreds of millions of renminbi in a Series C financing round. The funding round was led by GF Xinde Investment, with participation from Sun Rock Capital. The capital raised…
-
ETERN Therapeutics Secures Funding to Advance LLPS Platform and Clinical Trials for Anti-Tumor Drugs
•
ETERN Therapeutics, a Shanghai-based developer of small-molecule anti-tumor drugs, has announced the commencement of a Series B+ financing round. The initial phase of this funding round was co-led by the AZ-CICC Fund and another Wuxi-based fund, with participation from Wuxi Capital. The capital raised will be directed towards the construction…
-
Shanghai Unveils Massive Investment Projects and Funds to Boost High-Tech Industries
•
Shanghai has unleashed a flurry of policy-backed project signings and initiatives, marking a significant boost for key industries in the region. In the first quarter of 2024, a total of 420 major investment projects, each valued at over RMB 100 million (USD 13.8 million), were executed, culminating in a total…
-
Beijing’s Changping District and State-owned Capital Firm Launch RMB 20 Billion Healthcare Fund
•
The Changping district of Beijing municipality has reached an agreement with Beijing State-owned Capital Operation and Management Co., Ltd to establish a medical and healthcare industry fund worth RMB 20 billion (USD 2.77 billion). This Beijing-based fund will focus on pivotal sectors including innovative drugs, innovative medical devices, and emerging…
-
Merck Expands Global Footprint with Largest M Lab Collaboration Center in Shanghai
•
Merck KGaA (ETR: MRK), a leading German technology company, has announced the completion of the M Lab Collaboration Center in Shanghai, which is the largest among its global network of 10 such centers. This significant expansion represents an additional investment of EUR 14 million, resulting in the addition of a…
-
Sanofi Projects EUR 13 Billion in Dupixent Sales for 2024 Despite Q1 Challenges
•
Sanofi (NASDAQ: SNY), a leading French pharmaceutical company, has released its guidance for the first quarter of 2024. Despite expectations that its top-selling interleukin blocker Dupixent (dupilumab) will face challenges from a co-pay assistance program in the first quarter, the company projects that the drug’s sales will reach EUR 13…
-
Golden Leaf Med Tec Secures Series D Funding to Advance Hypertension and Diabetes Treatments
•
Shanghai Golden Leaf Med Tec Co., Ltd, a specialist in interventional treatments based in China, has reportedly secured “hundreds of millions” of renminbi in a Series D financing round. The round was led by ZhongPing Capital, with participation from Shanghai Healthcare Capital, Dingxin Capital, and Morning Spring Venture. The funds…
-
Astra Biotech Raises Tens of Millions in Pre-Series B Funding to Expand Diagnostic Capabilities
•
Astra Biotech, a developer of single molecule immunodiagnostic technology based in Suzhou, has reportedly raised “tens of millions” of renminbi in a pre-Series B financing round. The round was led by Zheng Xuan Investment, with participation from BioTrack Capital, Chuangshou Equity Investment, and others. The funds will be utilized to…
-
Horimed Secures Tens of Millions in Financing to Advance OCT Imaging Technologies
•
Horimed, a Tianjin-based manufacturer of OCT imaging equipment, has reportedly raised “tens of millions” of renminbi in a recent financing round. The round was led by existing investor Tasly Capital, with contributions from Haihe Fund and Haitai Capital. The proceeds will be allocated to research and development, manufacturing, regulatory filings,…
-
Beijing Varnotech Biopharm Secures RMB 600 Million in Series B Funding for Vaccine Development
•
Beijing Varnotech Biopharm Ltd, a China-based specialist in human vaccines, has successfully raised RMB 600 million (approximately USD 83 million) in a Series B financing round. The round was co-led by the Beijing Medical and Health Industry Investment Fund and Huayin Financial Investment, with additional contributions from Watere Capital, Beijing…
-
PoreSpect Secures Tens of Millions in Angel Funding Led by Forcefield Ventures
•
PoreSpect, a Guangdong-based manufacturer of devices and consumables, has reportedly secured “tens of millions” of renminbi in an angel financing round. The funding was led by Forcefield Ventures, with additional contributions from Tiantu Capital and Yael Capital. Founded by a team of pioneers in solid-state nanopore preparation and detection, PoreSpect…
-
Novo Nordisk Invests RMB 4 Billion to Expand Sterile Manufacturing in Tianjin
•
Novo Nordisk (NYSE: NVO), a Denmark-based leader in diabetes care, has announced a substantial investment of RMB 4 billion (USD 555.6 million) for the expansion of its sterile preparation manufacturing facility in Tianjin. Construction on the site has commenced, with completion expected by 2027. This strategic expansion is set to…
-
Shanghai Winpu Technology and Silver Mars Merge Under YinKe Holding to Accelerate Healthcare Innovation
•
Shanghai Winpu Technology Co., Ltd., a specialist in medical-grade polymer materials based in China, has announced a strategic merger with Silver Mars, a Suzhou-based high-tech firm specializing in bionic materials. The merged entity falls under the umbrella of YinKe Holding, a technology conglomerate with a focus on the healthcare sector.…
-
Microenergy Medical Technology Secures Pre-Series A Funding to Advance Medical Devices
•
Microenergy Medical Technology Co., Ltd, a Hangzhou-based manufacturer of active intervention medical devices, has reportedly secured “tens of millions” of renminbi in a pre-Series A financing round. The funding was led by TigerYeah Capital, with contributions from TriWise Capital and HUAGAI Capital. Established in 2021, Microenergy Medtech has a presence…
-
Fosun Pharma Launches RMB 5 Billion Fund to Boost Biopharmaceutical Investments in Shenzhen
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) has unveiled plans to establish a RMB 5 billion (USD 695 million) fund in collaboration with seven other investors, with Shenzhen FOF expected to contribute 50% of the total funding. The initiative aims to enhance resource sharing and cooperation between…
-
Simnova Secures RMB 200 Million in Series A+ Funding to Advance CAR Therapy Pipeline
•
Simnova, a Shenzhen-based developer of chimeric antigen receptor (CAR) adoptive cell therapies, has successfully raised RMB 200 million (approximately USD 27.8 million) in a Series A+ financing round. The round was led by Youshan Capital, with participation from SIP Oriza Seed Fund, PagodaTree Partners, and Triwise. The company’s pipeline features…
-
Merck’s 2023 Annual Report: A Mixed Bag Amid Global Challenges
•
Merck KGaA (ETR: MRK), a leading German chemical, reported a 5.6% decline in its global net sales for the fiscal year 2023, amounting to €21.0 billion ($23.0 billion). This contraction was partially attributed to the adverse impact of foreign exchange rates. The company’s Healthcare division, however, posted a 2.7% increase…
-
Zylox-Tonbridge Medical Technology Secures Licensing Deal with Avinger to Boost Device Portfolio
•
Zylox-Tonbridge Medical Technology (HKG: 2190), a China-based developer of nerve and peripheral vascular interventional devices, has announced a series of licensing and investment agreements with U.S. device manufacturer Avinger. The partnership aims to expand Zylox-Tonbridge’s portfolio of peripheral vascular intervention devices. According to the agreement, Zylox-Tonbridge will secure exclusive rights…
-
Proviva Therapeutics Secures $18 Million in Series A Financing to Advance PTX-912
•
Proviva Therapeutics, a Shanghai-based clinical-stage biotechnology company, has reportedly secured USD 18 million in a Series A financing round led by Lapam Capital, Ennovation Ventures, and Sangel Capital. The funds raised will be directed towards the clinical advancement of the company’s core product, PTX-912. Specializing in the development of next-generation…
-
Lundbeck A/S Posts 8.2% YOY Revenue Growth in 2023 with Strong Performance Across Key Therapies
•
Danish pharmaceutical company Lundbeck A/S (FRA: LDBB) has announced its financial results for 2023, highlighting an 8.2% year-on-year (YOY) increase in revenue to DKK 19.912 billion (USD 2.88 billion). The company is now under the leadership of CEO Charl van Zyl, who took over from Deborah Dunsire in October 2023.…
-
Bayer Posts 1.2% YOY Sales Decline in 2023 with Pharmaceuticals and Consumer Health Segment Updates
•
Germany’s Bayer (ETR: BAYN) has released its financial results for 2023, marking a year of declining sales that culminated in a 1.2% year-on-year (YOY) drop in constant currency and portfolio-adjusted terms, reaching €47.6 billion (USD 51.7 billion). The Pharmaceuticals segment generated €18.1 billion (USD 19.6 billion) with a 0.4% decline…
-
Vivolight Medical Secures Over RMB 100 Million in Strategic Financing to Boost Global Expansion
•
Shenzhen Vivolight Medical Device & Technology Co., Ltd, a Chinese medical device company nurtured and backed by the Chinese Academy of Sciences (CAS), has reportedly secured over RMB 100 million (USD 14.5 million) in strategic financing. The round was reportedly supported by Sinowisdom, Guangzhou Industrial Investment Fund, and Speedfox. The…
-
Sino-Biocan Secures Series B Funding to Boost Cell and Gene Therapy Production Platforms
•
Sino-Biocan (Shanghai) Biotech Ltd, a provider of automated, modularized, closed cell production platforms for the cell and gene therapy (CGT) sector, has reportedly secured RMB 100 million (USD 14.5 million) in a Series B financing round. The round was led by Dalton Venture, with additional investment from Qikun Fund and…
-
Angitia Bio Secures USD 40 Million in Series B+ Financing to Advance Musculoskeletal Disorder Therapies
•
Angitia Biopharmaceuticals, a Guangzhou-based developer of therapies for bone, joint, and muscle diseases, has announced the successful completion of a Series B+ phase II financing round, securing USD 40 million in funds. The round was led by YueKai Health Venture, with the proceeds earmarked to propel the global development of…
-
Viatris Eyes Growth After Concluding Initial Phase of Strategy with 2023 Sales at $15.4 Billion
•
US generics giant Viatris (NASDAQ: VTRS) reported a 4% year-on-year decline in global sales to USD 15.4 billion in constant currency terms, as detailed in the company’s 2023 financial report. Despite the dip, company president Rajiv Malik declared the completion of the first phase of Viatris’s strategic plan, with the…
-
Simcere Pharmaceutical’s Oncology Unit Raises RMB 970 Million to Advance Cancer Drug Development
•
Simcere Pharmaceutical Group (HKG: 2096) has announced that its oncology subsidiary, Simcere Zaiming Pharmaceutical Co., Ltd., has secured RMB 970 million (USD 135 million) in financing, elevating the company’s market valuation to RMB 8.47 billion (USD 1.2 billion). The funding round was led by CS Capital, which contributed RMB 800…
-
CardioACC Initiates Regulatory Study for Groundbreaking 7.5F Intracardiac Ultrasound System
•
CardioACC, a Shenzhen-based company specializing in cardiovascular interventional imaging and treatment technologies, has launched a regulatory study for its 7.5F 2D intracardiac ultrasound imaging system (ICE), successfully enrolling dozens of patients. This ultrasound catheter model is smaller than any currently marketed ICE products globally, nearing the industry’s design limits. The…
-
Sinopharm Plans to Privatize China Traditional Medicine Holdings in a USD 2 Billion Deal
•
China Traditional Medicine Holdings (HKG: 0570; China TCM) has announced that its controlling shareholder, the state-owned Sinopharm Group Co., Ltd (HKG: 1099), intends to take the company private. The proposed deal values China TCM at a price of HKD 4.6 per share, representing a 34% premium over the recent closing…
-
Shenzhen Eureka Biotechnology Secures RMB 300 Million in Series B+ Funding for CGT Expansion
•
Shenzhen Eureka Biotechnology Co., Ltd., a specialist in cell and gene therapy (CGT) based in China, has successfully raised over RMB 300 million (approximately USD 41.7 million) in a Series B+ financing round. The funding was led by Yuexiu Capital, with notable participation from Fortune Capital, Guangdong Technology Financial Group,…
-
Sinovent Secures USD 97.2 Million in Series E Financing to Boost Clinical Trials and Commercialization
•
Sinovent Inc., a Suzhou-based biopharmaceutical company, has announced the successful completion of a Series E financing round, raising RMB 700 million (USD 97.2 million). The round was co-led by Tencent Investment and Guoxin Investment, with additional contributions from Jinan Industrial Development Investment, Huakong Investment, Yuekai Securities, Sea of Stars Capital,…
-
AstraZeneca Reports 6% Revenue Growth in 2023, Driven by Oncology and Diabetes Drug Sales
•
AstraZeneca (AZ; NASDAQ: AZN), the UK-based multinational, reported its financial results for 2023 this week, revealing a 6% year-on-year increase in annual global revenues, reaching USD 45.8 billion at constant exchange rates. Oncology revenue surged by 21%, while cardiovascular, renal, and metabolism (CVRM) sales rose 18%. Respiratory and immunology (R&I)…
-
Gilead’s 2023 Flat Sales Reflect Stagnation and COVID-19 Demand Decline
•
Gilead Sciences Inc. (NASDAQ: GILD) has reported a stagnant performance for the year 2023, with total product sales remaining unchanged at USD 26.9 billion. Amid a broad decline in demand for COVID-19 treatments, the company’s antiviral Veklury (remdesivir) sales could not offset the downturn, although HIV sales increased by 6%…
-
Gilead’s 2023 Stagnation Foresees Flat 2024 Sales as Veklury Revenues Dwindle
•
Gilead Sciences (NASDAQ: GILD) has reported a stagnant performance for 2023, with product sales remaining flat at USD 26.9 billion. The company’s financials were affected by a widespread downturn in demand for COVID-19 treatments, as its antiviral Veklury (remdesivir) sales offset growth in other areas. HIV sales reached USD 18.2…
-
Amgen’s Q4 2023 Results Showcase 9% YOY Growth, 18 Drugs Hit Record Sales
•
Biopharmaceutical giant Amgen (NASDAQ: AMGN) has reported its financial results for Q4 2023, announcing annual sales of USD 26.9 billion, reflecting a substantial 9% year-on-year (YOY) increase, primarily driven by volume growth. In an earnings call, CEO Robert Bradway highlighted that a remarkable 18 of the company’s medicines achieved record…
-
Eli Lilly’s 2023 Revenue Soars on Metabolism Drugs, Anticipates Further Growth in 2024
•
Eli Lilly and Company (NYSE: LLY) reported a robust 2023 financial performance with a 20% year-on-year (YOY) increase in revenue, reaching USD 34.1 billion, as detailed in their Q4 2023 report released this week. This growth was substantially driven by the company’s metabolism drugs, indicating a recovery from the COVID-19…
-
BMS Sees Mixed Results in 2023: Growth in New Products Offset by Loss of Exclusivity
•
Bristol Myers Squibb (BMS; NYSE: BMY) reported a 2% year-on-year contraction in 2023 revenues, excluding foreign exchange effects, totaling $45.0 billion, according to its recently released financial report. The company’s global sales were bolstered by a 4% increase in in-line products, generating $34.3 billion, and a remarkable 76% surge in…
-
Matridx Bio Secures Series C+ Funding to Advance Infectious Pathogens Diagnostics
•
Hangzhou Matridx Biotechnology Co., Ltd, a specialist in molecular diagnostics for infectious pathogens based in China, has reportedly secured “hundreds of millions” of renminbi in a Series C+ financing round. The investment was led by a state-owned fund in Yuhang, Zhejiang province, and other undisclosed participants. The funds raised will…
-
Roche Posts Modest 2023 Growth Amid Shifts in Demand for COVID-Related Products
•
Swiss pharmaceutical giant Roche (SWX: ROG) has published its 2023 financial results, showing a modest 1% year-on-year (YOY) increase in global sales at constant exchange rates (CER) to CHF 58.7 billion (USD 68.5 billion). This growth was primarily due to a 6% YOY expansion in the pharmaceutical business to CHF…
-
Takeda Reports Flat 9-Month Revenue Growth Amid Pipeline Optimization Efforts
•
Takeda (TYO: 4502), a leading Japanese pharmaceutical company, has released its financial results for the 9-month period ended December 31, 2023, reporting a revenue of JPY 3.2 trillion (USD 21.9 billion) with a 0.0% growth at constant exchange rates (CER). The company’s performance was impacted by declines in oncology, neuroscience,…
-
Rebecca Tech Secures USD 10 Million in Series A++ Funding to Expand Micro RF Technology Globally
•
Rebecca Tech LLC, a Hangzhou-based manufacturer specializing in microelectromechanical RF (radiofrequency) technology, has announced the successful closure of a Series A++ financing round worth USD 10 million. The round was led by Med-Fine Capital, with participation from Puhua Leading Investment. The funds raised will be allocated towards the global promotion…
-
GSK Posts 5% YOY Growth in 2023 Financials, Vaccines Business Drives Expansion
•
GSK plc (NYSE: GSK), the UK pharmaceutical giant, announced its financial results for the fourth quarter and full-year 2023, with a 5% year-on-year (YOY) growth to GBP 30.3 billion (USD 38.5 billion) in revenue over the 12-month period. When excluding the impact of COVID-related products, the company’s sales surged by…
-
Novartis Sees Robust Growth in Innovative Medicines with 2023 Financials Reflecting a Shift Toward R&D Focus
•
Novartis (NYSE: NVS), the Swiss pharmaceutical giant, reported a substantial leap in its global sales for the last financial year, amassing USD 45.4 billion—a 10% year-on-year (YOY) increase in constant currency terms, as per the 2023 financials released this week. This achievement marks Novartis’s inaugural annual report following the strategic…
-
Shanghai CureGene Pharmaceutical Secures USD 14 Million in Series B Financing to Advance Cardiovascular Treatments
•
Shanghai CureGene Pharmaceutical Co., Ltd, a Chinese biopharmaceutical company, has announced the successful completion of a Series B financing round, raising RMB 100 million (USD 14 million). The financing was led by Tailong Capital, with additional investments from Elikon Venture and TigerYeah Capital, as well as participation from existing investors…
-
Mindray to Acquire 21.12% Stake in APT Medical for RMB 6.652 Billion
•
Mindray (SHE: 300760), a leading China-based medtech firm, has announced plans to acquire a 21.12% stake in APT Medical Inc., a Shenzhen-based specialist in cardiac electrophysiology that went public on Shanghai’s STAR market in 2021. The acquisition will cost Mindray approximately RMB 6.652 billion (USD 926.6 million). Additionally, Mindray will…
-
BJ Bioscience Inc. Faces Bankruptcy as Hangzhou Court Accepts Liquidation Application
•
The Hangzhou Yuhang District People’s Court has released a document indicating that BJ Bioscience Inc.’s application for bankruptcy liquidation has been accepted for review. The Hangzhou-based firm becomes the first domestic biotech company to face insolvency this year. Established in 2018, BJ Bio focused on research and development (R&D) of…
-
Shanghai’s Reunion Biotech Secures Series B Funding to Advance Hydrogel Products
•
Reunion Biotech, a Shanghai-based medical hydrogel manufacturer, has reportedly secured nearly RMB 100 million (USD 14 million) in a Series B financing round. The funding was led by Dingxin Capital, with existing investors Qiming Venture Partners and Conson Financial Holdings contributing to the oversubscribed round. The proceeds will be allocated…
-
Digital Precision Medicine Secures Over $28 Million in Series C Financing
•
Digital Precision Medicine (DPM), a molecular imaging technology developer incubated by the Chinese Academy of Sciences (CAS) and comprising Beijing Digital Precision Medical Technology Co., Ltd, and Zhuhai Dipu Medical Technology Co., Ltd, has reportedly raised over RMB 200 million (USD 28 million) in a Series C financing round. The…
-
Endoso Life Raises Over $14 Million in Series A to Expand Endoscope Product Lines
•
Endoso Life, a developer of high-end medical endoscope systems headquartered in Hangzhou, has reportedly secured more than RMB 100 million (USD 14 million) in a Series A financing round. The round was led by WEGO’s fund, with additional investment from Lapam Capital. The funds raised will be directed towards expanding…
-
Bayer Unveils New Operating Model to Drive Profitable Growth Amid Challenges
•
Facing a challenging business landscape, Germany’s Bayer (ETR: BAYN) has announced a new operating model aimed at enhancing its performance and returning to profitable growth. The plan includes significant job cuts as part of an ongoing staff reduction program, with compulsory redundancies set to begin in 2027. In contrast to…
-
Shanghai’s EnjoSim Secures Tens of Millions in Pre-Series A Funding for Expansion
•
EnjoSim, a Shanghai-based developer of microbiologic self-administration systems, has reportedly secured tens of millions of renminbi in a Pre-Series A financing round. The funds will be directed towards scaling up the operation of multiple fully automatic production lines, developing new products, and expanding the company’s business reach both within China…
-
Changchun High & New Technology to Transfer 7.42% Stake to Ex-Wife in Divorce Settlement
•
Changchun High & New Technology Industries (Group) Inc., (SHE: 000661) has announced plans to transfer 30,014,100 shares, representing a 7.42% stake, to Wang Simian, the ex-wife of company shareholder Jin Lei and founder of subsidiary Changchun GeneScience Pharmaceutical Co., Ltd., as part of their divorce agreement. Based on the estimated…
-
Keylights Biotechnology Raises $14 Million in Series B to Expand IVD Instrument Range
•
Keylights Biotechnology Co., Ltd., a leading in vitro diagnostic (IVD) instruments manufacturer headquartered in Shenzhen, has reportedly secured nearly RMB 100 million (USD 14 million) in a Series B financing round. The round was led by Luxin Venture Capital, with participation from Hanchi Venture Capital. The funds raised will be…
-
C4 Therapeutics Outlines 2024 Focus Amid 30% Workforce Reduction, Prioritizes Key Oncology Trials
•
C4 Therapeutics (NASDAQ: CCCC), a leader in protein degradation, announced this week its strategic focus for 2024, which includes a significant reduction of 30% in its workforce. The U.S.-based company will prioritize ongoing Phase I/II trials for CFT7455 and CFT1946, targeting relapsed/refractory multiple myeloma (r/rMM) and BRAF V600X-mutant solid tumors,…
-
Synvida Raises Nearly RMB 200 Million in Series A Funding to Advance Clinical Studies
•
Synvida, a biotech company incubated by Shanghai Pharma (HKG: 2607, SHA: 601607) and Shanghai Healthcare Capital (SHC), has reportedly secured nearly RMB 200 million (approximately USD 28 million) in a Series A financing round led by Lapam Capital, with participation from SHC. The funds will be allocated to clinical and…
-
Bebig Medical Group Secures Over USD 14 Million in Series B Financing to Boost Radiotherapy Technology
•
Bebig Medical Group, a Germany-based provider of high-quality radiation therapy products with a presence in China and the United States, has reportedly secured over RMB 100 million (USD 14 million) in a Series B financing round. The sole investor in this round was Cathay Capital. The funds raised are intended…
-
Bayer AG Leads Series D Investment in Jixing Pharmaceuticals, Eyeing Commercialization Rights
•
Bayer AG (ETR: BAYN, OTCMKTS: BAYRY), a leading German pharmaceutical company, has announced a long-term collaboration with Jixing Pharmaceuticals, a China-based firm, following its leadership in a Series D financing round. The investment is being made in conjunction with RTW Investments, the fund that established and supported Jixing. Bayer’s venture…
-
Novartis to Fully Acquire SanReno Therapeutics to Expand Kidney Drug Portfolio in China
•
Novartis (NYSE: NVS), a Swiss pharmaceutical giant, has announced plans to acquire the remaining shares in SanReno Therapeutics, a Shanghai-based developer of kidney drugs. This move is aimed at bolstering Novartis’s kidney product portfolio in China. The financial details of the transaction have not been disclosed. SanReno Therapeutics was established…
-
Ningbo Linstant Polymer Materials Secures Over USD 14 Million in Series B Financing to Boost Production and Global Reach
•
Ningbo Linstant Polymer Materials Co., Ltd, a Chinese manufacturer specializing in polymer accessories for medical devices, has reportedly secured over RMB 100 million (USD 14 million) in a Series B financing round. The funding was led by Fenghua VC, with additional investments from NTG. The company plans to use the…
-
OnCusp Therapeutics Secures Oversubscribed USD 100 Million Series A Financing for CDH6-Targeting ADC
•
OnCusp Therapeutics, a U.S.-based biopharmaceutical company, has closed an oversubscribed Series A financing round, raising USD 100 million. The round was led by Novo Holdings, OrbiMed, and F-Prime Capital, with significant contributions from BioTrack Capital, a Chinese investor involved in OnCusp’s seed funding, Catalio Capital Management, Marshall Wace, Forge Life…
-
Suzhou Elite Analytical Instruments Secures Over $14 Million in Initial Funding Round
•
Suzhou Elite Analytical Instruments Co., Ltd, a leading specialist in liquid chromatography based in China, has reportedly raised more than RMB 100 million (USD 14 million) in its first-ever financing round. The funding was co-led by Jifeng Ventures and SND Rongsheng Investment, with additional investments from SIDVC, Qiaojing Capital, New…
-
Beijing Avistone Pharmaceuticals Raises RMB 1 Billion in Series B Funding to Accelerate Drug Development
•
Beijing Avistone Pharmaceuticals Biotechnology Co., Ltd, based in China, has successfully closed its Series B funding round, raising RMB 1 billion (approximately USD 140 million). The round was jointly led by CS Capital and IDG Capital, with additional contributions from YanChuang Group, Cathay Capital, and existing investor Bain Capital. The…
-
TYK Medicines Secures Nearly RMB 200 Million in Series D Financing Led by Sichuan Huiyu Pharmaceutical
•
Shanghai-based TYK Medicines (HKG: 2410) has successfully completed a Series D financing round, raising nearly RMB 200 million (approximately USD 28 million). The round was led by Sichuan Huiyu Pharmaceutical Co., Ltd. (SHA: 688553), with additional investments from CICC Capital, Changxing Financial Holding, and the Huzhou Talent Fund. Founded in…
-
Panlin Capital Raises Second Fund Focused on Biopharmaceutical Innovation
•
Panlin Capital has announced the successful closing of its second venture capital fund, the Hangzhou Panlin Xukang Fund, which will concentrate on innovative biopharmaceuticals, medical devices, and biotechnology sectors. This marks the first fund established by Panlin Capital in Hangzhou and the second venture capital fund raised by the firm…
-
XRGenesis Raises $14 Million in Series A to Advance Ophthalmic Surgical Technology
•
XRGenesis, a developer of high-end ophthalmic surgical equipment based in Hangzhou, has reportedly raised nearly RMB 100 million (USD 14 million) in a Series A financing round. The round was led by Legend Capital, with participation from existing investors TIgerYeah Capital, Proxima Ventures, Dalton Venture, and Tao Capital. The funds…
-
Kossel Medtech Secures Over $14 Million in Series B Financing to Boost International Expansion
•
Kossel Medtech (Suzhou) Co., Ltd., a company specializing in coronary and peripheral intervention medical devices, electrophysiology series products, and related accessories, has reportedly secured over RMB 100 million (USD 14 million) in a Series B funding round. The round was led by Fortune Capital, with additional investments from SIDVC, SND,…
-
China Grand Pharmaceutical to Acquire Majority Stake in Mitsubishi Tanabe’s Tianjin Subsidiary
•
China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512; CGP) has announced its intention to acquire a 75.35% controlling stake in the Tianjin subsidiary of Japan-based Mitsubishi Tanabe Pharma Corporation for a consideration of HKD 400 million (USD 51 million). This strategic move signifies CGP’s expansion into a broader range…
-
Reetoo Biotechnology Boosts AI in Medical Diagnostics with $14 Million Funding Round
•
Shenzhen Reetoo Biotechnology Co., Ltd, a Chinese firm at the forefront of integrating artificial intelligence with medical diagnostics, has reportedly secured over RMB 100 million (USD 14 million) in a Series B2 financing round. The round was led by CAS Investment and a prominent Chinese fund, with additional participation from…
-
Mingyi Zhizao Secures $14 Million to Scale Gene Sequencing Platform and Production
•
Shenzhen Mingyi Zhizao Technology Co., Ltd, a Chinese company specializing in the gene sequencing industry, has reportedly secured nearly RMB 100 million (USD 14 million) in a Series B++ funding round led by Tenykin Capital and Jiangsu Jinqiao Private Equity Fund. The fresh capital is earmarked for the expansion of…
-
Zelgen Biopharmaceuticals Partners with Grand Life Sciences for Exclusive Marketing of Recombinant Human Thrombin
•
Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) has announced an exclusive marketing promotion service agreement with Grand Life Sciences Co., Ltd., aimed at advancing the commercialization of Zelgen’s recombinant human thrombin product in Greater China. Under the terms of the agreement, Grand Life will serve as the sole marketing promotion…
-
Sanofi Eyes Blockbuster Potential with 12 Pipeline Assets, Projects EUR 10 Billion in Annual Sales by 2030
•
Sanofi (NASDAQ: SNY) this week outlined its growth potential for the 2024 to 2025 period, highlighting a pipeline of 12 assets poised to achieve blockbuster status, including three projected to exceed EUR 5 billion in sales. The French pharmaceutical giant anticipates generating over EUR 10 billion in annual pharmaceutical revenues…
-
Hisilicon Medical Technology Secures Nearly RMB 100 Million in Series A Funding
•
Guangdong Hisilicon Medical Technology Co., Ltd., a China-based firm, has successfully raised nearly RMB 100 million (approximately USD 13.9 million) in a Series A financing round led by Qiaojing Capital. The funding round also attracted participation from notable investors including Hongcheng Investment, RongTong Capital, Chiron Ventures, and Zhejiang Innovation and…
-
J&J Forecasts 5-7% CAGR Through 2030, Driven by Innovative Medicine and Device Growth
•
Johnson & Johnson (J&J; NYSE: JNJ) has presented an update on its business strategy, pipeline, and financial outlook amidst the loss of exclusivity for its blockbuster immunosuppressant Stelara (ustekinumab) in the US. The company anticipates operational sales growth of 5% to 6% in 2024 and 3% or more in 2025,…
-
China’s Betta Pharmaceuticals Advances CFT8919 for EGFR-Mutated NSCLC After NMPA Approval
•
Betta Pharmaceuticals Co., Ltd (SHE: 300558), a Chinese pharmaceutical company, has announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a clinical study for CFT8919, a metamorphic BiDA degradation agent licensed from U.S. firm C4 Therapeutics, Inc. (NASDAQ: CCCC). The study will focus on…
-
Abbisko Therapeutics Strikes Licensing Deal with Merck KGaA for CSF-1R Inhibitor Pimicotinib
•
Abbisko Therapeutics Co., Ltd (HKG: 2256), a Shanghai-based biotechnology company, has announced a licensing agreement with German pharmaceutical giant Merck KGaA for its in-house developed colony stimulating factor-1 receptor (CSF-1R) inhibitor, pimicotinib (ABSK021). According to the agreement, Merck will secure an exclusive license to commercialize pimicotinib in mainland China, Hong…
-
Aspen Pharmacare Holdings to Boost China Presence with Full Acquisition of Sandoz’s Subsidiary
•
Aspen Pharmacare Holdings (JSE: APN), a South Africa-based pharmaceutical company, is poised to enhance its footprint in the Chinese market with the full acquisition of Sandoz’s (SWX: SDZ) China subsidiary, Sandoz (China) Pharmaceutical Co., Ltd. This acquisition will grant Aspen all commercial and intellectual property rights to the subsidiary’s existing…
-
SanegeneBio Secures Over USD 80 Million in Series A+ Funding to Advance RNAi Therapeutics
•
SanegeneBio, a Suzhou-based developer of RNA interference (RNAi) therapeutics, has successfully raised over USD 80 million in a Series A+ financing round co-led by Tencent Investment and YuanBio Venture Capital. The funding round also saw participation from Northern Light Venture Capital, C&D Emerging Industry Equity Investment, Yuanhe Holding, Shanghai Healthcare…
-
Bosscome Science & Technology Secures Series A Funding for Precision Medical Navigation Systems
•
Bosscome Science & Technology, a Chongqing-based developer of integrated optical and magnetic navigation systems, has reportedly secured “tens of millions” of renminbi in a Series A financing round led by Zhongxi Life Investment Partnership and Rayfund Investment. The funds raised will be allocated towards market promotion of its submillimeter level…
-
Taihe Weiye Biotechnology Secures RMB 300 Million in Series A+ Financing to Expand Production
•
Chengdu Taihe Weiye Biotechnology Co., Ltd, a Chinese developer of protected amino acids drugs, has reportedly secured nearly RMB 300 million (USD 42 million) in a Series A+ financing round, following its RMB 200 million (USD 28 million) Series A funding in August this year. The latest round was co-led…
-
Bayer Faces Backlash After Bond Sale Preceding Late-Stage Pipeline Failure
•
German pharmaceutical giant Bayer (ETR: BAYN) is facing investor and analyst scrutiny following its issuance of USD 5.75 billion in bonds shortly before disclosing a significant setback in its late-stage pipeline. The company issued the 3 to 30-year maturity bonds on November 16, and then announced the early termination of…
-
Beijing QL Biopharmaceutical Boosts Pipeline with RMB 200 Million Series B+ Round
•
Beijing QL Biopharmaceutical Co., Ltd., a Chinese biopharmaceutical company, has reportedly secured nearly RMB 200 million (USD 28 million) in a Series B+ financing round. The round was led by IMEIK Technology and China-US Green Fund, with additional investments from Jiayuan Fund, Chengdu Capital Group, Lanchi Ventures, and other parties.…
-
OrbusNeich Medical Group to Acquire Majority Stake in Indonesian Distributor PT Revass Utama Medika
•
OrbusNeich Medical Group Ltd (HKG: 6929), a Wholly Owned Foreign Enterprise (WOFE) specializing in vascular intervention based in Shenzhen, is poised to acquire an 84% stake in Indonesia-headquartered PT Revass Utama Medika for a consideration between USD 10.08 million to USD 20.16 million. PT Revass Utama Medika, which is focused…
-
Broncus Medical and Hangzhou Norchant Terminate Licensing Agreement with Cancellation Fee
•
Broncus Medical Inc., (HKG: 2216) a provider of lung disease precision intervention solutions with operations in Shanghai and Hangzhou, China, and San Jose and Seattle, United States, has announced the termination of a licensing agreement between its subsidiary Broncus Medical and Hangzhou Norchant, which was originally signed in September 2021.…
-
AbbVie Sues to Protect Rinvoq from Generic Competition in the US Market
•
AbbVie (NYSE: ABBV) has initiated legal action in the US to safeguard its blockbuster drug Rinvoq (upadacitinib) from generic market entries by Switzerland-based Sandoz (SWX: SDZ) and Indian pharmaceutical companies Aurobindo Pharma (NSE: AUROPHARMA), Hetero Labs, Intas Pharmaceuticals, and Sun Pharmaceutical (NSE: SUNPHARMA). Despite holding patents on the JAK inhibitor…
-
Zhejiang Huanqing Medical Technology Secures Series A Financing for Heart Failure Innovations
•
Zhejiang Huanqing Medical Technology Co., Ltd, a Chinese specialist in heart failure solutions, has reportedly raised “tens of millions” of renminbi through a Series A financing round. This funding was facilitated by notable investors including Zhangjiang Leading VC, Haining Juan Lake Dream Technology Fund, Tailong VC, and Tahoe Venture Investment.…
-
True Health Secures Over RMB 100 Million in Series B+ Financing for Surgical Robot Development
•
True Health, a Guangdong-based surgical robot developer backed by Gree Group, has reportedly raised over RMB 100 million (approximately USD 14 million) in a Series B+ financing round. This significant funding will be allocated to enhance research and development efforts, accelerate innovation in the surgical robot sector, and procure essential…
-
Bayer Halts Late-Stage Trial for Asundexian After Underperformance
•
Germany-headquartered Bayer (ETR: BAYN) announced the termination of a late-stage trial for its antithrombotic candidate asundexian. Asundexian, once considered a potential blockbuster, was outperformed by the standard of care in preventing stroke and systemic embolism in patients with atrial fibrillation, the most lucrative indication for the drug, with an estimated…
-
Dizal Pharmaceutical and Wuxi Gaofa Investment to Establish Joint Venture for Auto-Immune Disease Treatments
•
China-based AstraZeneca (AZ, NASDAQ: AZN) spin-out, Dizal Pharmaceutical Co., Ltd (SHA: 688192), has entered into a cooperation framework agreement with Wuxi Gaofa Investment Development Group Co., Ltd to establish a joint venture (JV). The JV will focus on the research, development, manufacturing, and sale of golidocitinib and DZD8586, which are…
-
Asia Regenerative Medicine Secures Pre-Series A Financing for Bioartificial Organ Development
•
Shenzhen-based bioartificial organ developer, Asia Regenerative Medicine, has reportedly raised tens of millions of renminbi in a pre-Series A financing round. The round was led by Dee Capital, with additional investments from West Lake Photonics, HWealth Capital, Topology Capital, Xiamen Gaoxin Kechuang Angel Venture Capital Co., Ltd, and Ke Xi…
-
VIVA Biotech Holdings Secures Nearly USD 210 Million in Financing Round
•
China-based Contract Research Organization (CRO) VIVA Biotech Holdings (HKG: 1873) has announced the completion of a financing round, securing close to USD 210 million with backing from Temasek, Highlight Capital (HLC), and True Light. The Viva Biotech Holdings group obtained nearly USD 150 million through the transfer of approximately 24.21%…
-
Fosun Pharmaceutical’s US Subsidiary Partners with Treehill Partners for Clinical-Stage Investments
•
Fosun Pharmaceutical (Group) Co., Ltd (HKG: 2196; SHA: 600196) through its US subsidiary, Fosun Pharma USA, is partnering with Treehill Partners, a US-based financial and deal-making advisory firm specializing in the healthcare sector. The collaboration aims to establish a jointly operated investment vehicle targeting individual clinical-stage assets. Targeting High-Potential Clinical-Stage…
-
WuXi Biologics’ Subsidiary WuXi XDC Lists on Hong Kong Stock Exchange
•
WuXi Biologics (HKG: 2269) has successfully spun off its conjugate drug-focused subsidiary, WuXi XDC Cayman Inc., (HKG: 2268) to the Hong Kong Stock Exchange on Friday, November 17, 2023. Through the global offer, WuXi XDC issued 178.44 million shares at a price of HK 20.60 per share. The gross proceeds…
-
PRECEDO Secures Over RMB 100 Million in Financing to Build Living Primary Cancer Cell Bank
•
PRECEDO, a leading cell engineering specialist headquartered in Hefei, has reportedly secured more than RMB 100 million (USD 13.8 million) in a recent financing round. This capital injection, which includes investment from Sunland Fund and other financial backers, will be directed towards the construction of the renewable Living Primary Cancer…
-
Huadong Medicine Co., Ltd Secures Partnership and Commercial Rights for Yuyan’s Botulinum Toxin
•
China-based Huadong Medicine Co., Ltd (SHE: 000963) has entered into an equity investment and partnership agreement with Chongqing Yuyan Pharmaceutical Co., Ltd. This strategic alliance involves a significant investment and the acquisition of exclusive commercialization rights for Yuyan’s medical aesthetics product in key regions. Investment and Stake AcquisitionAs per the…
-
Boehringer Ingelheim and Scottish Enterprise Co-Lead GBP 4.3M Seed Funding for Glox Therapeutics
•
Germany’s Boehringer Ingelheim, in collaboration with Scotland’s national economic development agency Scottish Enterprise, has co-led a GBP 4.3 million (USD 5.3 million) seed funding round for Scotland-based biotechnology company Glox Therapeutics. The investment will enable Glox to establish new laboratories and expand its team, bolstering its mission to develop precision…
-
Beijing-Based Immupeutics Medicine Secures Tens of Millions in Pre-Series A+ Financing
•
Immupeutics Medicine, a Beijing-based developer in the field of tumor immunotherapy, has reportedly secured tens of millions of renminbi in a pre-Series A+ financing round. The funding round was led by Beijing state-owned Capital Operation and Management Center, with additional investments from Junshi Bio, Alwin Capital, and the company’s founder.…
-
Merck Reports Q3 2023 Financial Results with Mixed Performance Across Segments
•
Germany-based Merck (ETR: MRK) has released its financial results for the third quarter of 2023, revealing a 4.1% year-on-year (YOY) decline in organic sales, totaling EUR 5.2 billion (USD 5.5 billion) for the three-month period. The results highlight a challenging environment, with only the Healthcare division showing growth. The Healthcare…
-
Sandoz Enters Euro Debt Market with $2.1 Billion Eurobond Issuance
•
Switzerland-based Sandoz (SWX: SDZ), a leader in the generics and biosimilars market, has successfully entered the Euro debt capital market by issuing three inaugural Eurobond debt instruments, raising EUR 2.0 billion (USD 2.1 billion). This capital will be combined with a previous CHF issuance to repay a bridge loan of…
-
Zhejiang Boner Medical Secures Over RMB 800 Million in Pre-IPO Financing for Strategic Expansion
•
Zhejiang Boner Medical Investment Management Co., Ltd., known as Bang-er Orthopedics, a leading hospital investment operator focused on orthopedics and rehabilitation, has reportedly raised over RMB 800 million (USD 110 million) in a pre-IPO financing round. The round was led by C&D Emerging Industry Equity Investment, with participation from Sunshine…
-
Bayer’s Q3 2023 Financial Report: A Mixed Bag with Consumer Health Driving Growth
•
Germany-based major Bayer (ETR: BAYN) published its financial report for the third quarter of 2023, revealing global sales of EUR 35.8 billion (USD 38.3 billion) between Q1 and Q3, marking a 3.2% year-on-year (YOY) decline. Despite this, the company confirmed its 2023 guidance of EUR 48.5 billion to EUR 49.5…
-
CIIE 2023: Danaher, Boehringer-Ingelheim, Merck, J&J, BeiGene, and Fosun Pharma Announce China Partnerships
•
The 6th China International Import Expo (CIIE) held in Shanghai this week has been a platform for multiple companies to announce their strategic partnerships in China. Among the notable participants are Danaher (NYSE: DHR), Boehringer-Ingelheim (BI), Merck Sharp & Dohme (MSD, NYSE: MRK), Johnson & Johnson (J&J, NYSE: JNJ), BeiGene…
-
Worg Pharmaceuticals Expands into Spain with Acquisition of Diater for EUR 150 Million
•
Worg Pharmaceuticals, a Hangzhou-based developer of allergic drugs, has formally entered the Spanish market by obtaining the necessary regulatory approval and completing the acquisition of local biopharmaceutical company Diater from fund manager Nazca Capital for approximately EUR 150 million (USD 160 million). This strategic move marks a significant expansion for…
-
Senti Biosciences and Celest Therapeutics Partner on CAR-NK Cell Therapy Clinical Trial in China
•
Senti Biosciences Inc., (NASDAQ: SNTI), a San Francisco-based biotech company, has announced a strategic collaboration and license agreement with Shanghai-based Celest Therapeutics Co., Ltd. The partnership will see Celest manage a pilot clinical trial in mainland China for Senti’s SENTI-301A, an off-the-shelf CAR-NK cell therapy targeting GPC3-expressing tumors. Senti will…
-
Qingdao’s Raise Care Secures Over RMB 100 Million in Series B Financing Led by CITIC Capital
•
Qingdao-based Raise Care has reportedly secured upwards of RMB 100 million (USD 13.7 million) in a Series B financing round, according to recent reports. The round was led by CITIC Capital’s healthcare fund, with participation from CICC Capital, Jufeng S&T Venture Investment, and other investors. Company Background and FocusFounded in…
-
Novo Nordisk Reports 33% YOY Growth in Q3 2023 with Diabetes and Obesity Care Driving Sales
•
Denmark-based pharmaceutical giant Novo Nordisk (NYSE: NVO) has released its Q3 2023 earnings report, showcasing a 33% year-on-year (YOY) growth in constant exchange rates (CER) to DKK 166.4 billion (USD 23.7 billion) over the first nine months. The company identified diabetes care and obesity care as the key growth drivers,…
-
Pfizer Inc. Reports Q3 2023 Revenue Contraction and Launches Cost Realignment Program
•
US pharmaceutical giant Pfizer Inc., (NYSE: PFE) has released its financial results for the third quarter of 2023, reporting a contraction of -41% year-on-year (YOY) in operational terms to USD 13.2 billion, excluding foreign currency fluctuations. The quarter was marked by a net loss of USD 2.38 billion, the company’s…
-
Daiichi Sankyo Reports 19.5% YOY Revenue Growth in First Half of Fiscal 2023
•
Japan’s Daiichi Sankyo (TYO: 4568) reported a robust 19.5% year-on-year (YOY) increase in revenue for the six months ended September 30, 2023, reaching JPY 726.3 billion (USD 4.8 billion), according to the company’s financial report published this week. This growth was driven by a combination of factors, including the depreciation…
-
GSK Reports Modest 2% YOY Growth in Q3 2023 Finances, Vaccines Unit Soars 24%
•
UK-based pharmaceutical giant GlaxoSmithKline (GSK; NYSE: GSK) has released its financial report for the third quarter of 2023, showing mixed results over the first three quarters. The company experienced a modest 2% year-on-year (YOY) expansion, reaching GBP 22.3 billion (USD 27.7 billion) at constant exchange rates. Vaccines Unit and General…
-
WE LINKING Secures Angel Financing for Implantable Brain Computer Interface Development
•
Shenzhen-based company WE LINKING, a specialist in implantable brain computer interfaces (BCI), has reportedly raised tens of millions of renminbi in an angel financing round. The round was led by Gaorong Capital, with additional investments from Beijing Life Science Park Innovation Investment Fund, Qiji Investment, and existing investor CDH Investments.…
-
ImmuXell Biotech Secures Over RMB 100 Million in Series A Funding for Cell Therapy Development
•
ImmuXell Biotech Co., Ltd, a Shanghai-based cell therapy developer, has reportedly secured over RMB 100 million (USD 13.7 million) in a Series A financing round. The round was led by SDIC Venture Capital, with significant participation from Huangpu Pharmaceutical Fund and Yuanxi Haihe Fund. The funds will be instrumental in…
-
Bio-Techne Corporation Reports 2% YOY Revenue Growth in Q1 2024 Fiscal Report
•
US-based life sciences service provider Bio-Techne Corporation (NASDAQ: TECH) has released its Q1 report for the fiscal year 2024, which ended on September 30, 2023. The company reported a 2% year-on-year (YOY) increase in revenues, reaching USD 276.9 million. Segment Performance and Revenue BreakdownBio-Techne’s Protein Sciences segment contributed USD 204.7…
-
AnHeart Therapeutics Signs Exclusive License Deal with Nippon Kayaku for Taletrectinib
•
China-based AnHeart Therapeutics has announced the signing of an exclusive license deal with Japan-based biopharma Nippon Kayaku Co., Ltd. This strategic partnership grants Nippon Kayaku marketing and distribution rights for AnHeart’s leading pipeline candidate, taletrectinib, a next-generation ROS1 inhibitor. Taletrectinib: A Promising Treatment for ROS1-Positive NSCLCTaletrectinib is an oral, potent,…
-
Amgen Reports Q3 2023 Financials: 5% Growth Driven by Volume Expansion
•
Amgen (NASDAQ: AMGN) has released its Q3 2023 financial results, showcasing a 5% year-on-year (YOY) increase in global sales, reaching USD 6.5 billion. This growth comes despite a 3% decrease in net selling price, primarily fueled by an impressive 11% increase in volume. Notably, this marks the company’s fourth consecutive…
-
Danyang Huichuang Secures Over USD 13.7 Million in Series B Funding for fNIRS Development
•
Danyang Huichuang Medical Equipment Co., Ltd, a China-based specialist in functional near-infrared spectroscopy (fNIRS), has reportedly secured over RMB 100 million (USD 13.7 million) in a Series B financing round. The funding round was led by Zhongke Haichuang, with additional contributions from Addor Capital, and existing investors Tsingyua Capital and…
-
AbbVie’s Q3 2023 Report Shows 6.0% YOY Decline in Net Revenues
•
AbbVie (NYSE: ABBV) released its Q3 2023 financial report last week, revealing a 6.0% year-on-year (YOY) decline in net revenues for the first nine months of the year, amounting to USD 40.0 billion. The decrease was attributed to underperformance across most business areas, with the exception of neuroscience, which reported…
-
Dr. Reddy’s Laboratories Reports 9% YOY Revenue Growth in Q2 2024 Fiscal Year
•
India-based generics giant Dr. Reddy’s Laboratories Ltd (NYSE: RDY) has released its financial report for the Q2 2024 fiscal year ended September 30, 2023. The company reported consolidated revenues of USD 828 million for the quarter, marking a 9% year-on-year (YOY) increase. This growth was primarily driven by robust generic…
-
Sanofi SA Reports Q3 2023 Financials with Focus on R&D and Dupixent Growth
•
French pharmaceutical giant Sanofi SA (NASDAQ: SNY) released its Q3 2023 financial results, reporting a net sales decrease of -4.1% year-on-year (YOY) but an increase of 3.2% in constant currency terms, reaching EUR 11.96 billion (USD 12.64 billion). Despite maintaining the forecast for 2023 earnings per share (EPS) growth, Sanofi…
-
BMS Revenue Slips Due to Revlimid Erosion: Q3 2023 Insights
•
Bristol Myers Squibb (BMS; NYSE: BMY) reported a 3% year-on-year (YOY) revenue decline, excluding foreign exchange impact, to USD 11.0 billion for Q3 2023, as detailed in the company’s recently released financial report. The downturn was primarily attributed to a significant 41% YOY drop in sales of the multiple myeloma…
-
Sonosemi Medical Secures Over USD 27.3 Million in Series B Funding for Vascular Intervention Devices
•
Sonosemi Medical Co., Ltd., a Shenzhen-based innovator in vascular graft intervention devices, has reportedly secured over RMB 200 million (USD 27.3 million) in a Series B financing round. The round was co-led by Yuexiu Industrial Investment Fund and CCB PE, with significant contributions from Tencent Investment, Eight Roads, and Alwin…
-
Novartis Q3 Earnings Reflect Strong Growth Post-Sandoz Spinoff
•
Novartis (NYSE: NVS) has released its Q3 2023 financial results, marking the first report since the company sharpened its focus on innovative medicines following the spinoff of Sandoz (SWX: SDZ) earlier this month. The financials reveal a robust performance with net sales reaching USD 34.0 billion for the first nine…
-
Leadinno Medical Valley Secures Series A+ Funding for Neuroregulation Device R&D
•
Leadinno Medical Valley, a Beijing-based innovator in pain management and neuroregulation devices, has reportedly secured over RMB 100 million (USD 15.7 million) in a Series A+ financing round. The funding, led by Dachen Caizhi Fortunevc with additional contributions from Wuxi Zhaoze Lifeng Investment, is earmarked for the research and development…
-
OrbiMed Raises Over USD 4.3 Billion for Private Investment Funds Focused on Healthcare
•
US-based investment fund giant OrbiMed has announced the successful raising of over USD 4.3 billion for its latest private investment funds. The capital will be distributed among OrbiMed Private Investments IX, OrbiMed Asia Partners V, and OrbiMed Royalty & Credit Opportunities IV, reflecting the firm’s commitment to expanding its reach…
-
Changchun BCHT Biotechnology Invests in Influenza Vaccine Production Expansion
•
China-based Changchun BCHT Biotechnology Co., Ltd (SHA: 688276) has announced plans to invest RMB 805 million (USD 110 million) in the production of 10 million annual doses of its influenza virus split vaccine (BK-01 adjuvant). This substantial investment includes RMB 659 million for industrialization and RMB 146 million for operational…
-
CBC HIP Secures USD 875 Million for Life Science Real Assets Venture CLSRA
•
CBC Healthcare Infrastructure Platform (CBC HIP), a prominent independent life science real assets investor in China, has reportedly closed its second funding round at USD 875 million for its inaugural life science real assets venture, CLSRA Venture I. This significant milestone includes the participation of Abu Dhabi-based sovereign investor Mubadala…
-
Roche’s Q3 2023 Report Shows 1% Global Growth Amid Lower COVID-19 Product Demand
•
Swiss pharmaceutical giant Roche (SWX: ROG) released its Q3 2023 report, indicating that a reduced demand for COVID-19 products impacted global growth, resulting in a 1% year-on-year (YOY) increase at constant exchange rates over the first nine months, with total sales amounting to CHF 44.1 billion (USD 49.4 billion). Excluding…
-
AlphaGen Therapeutics Secures Seed Funding for Pb-212 Radioligand Therapy Development
•
AlphaGen Therapeutics Ltd, a Shanghai-based developer specializing in radioligand therapy (RLT), has reportedly secured “tens of millions” of US dollars in a seed financing round co-led by Eight Roads. The funds will be instrumental in accelerating the clinical development of the company’s Pb-212 pipeline and in constructing a state-of-the-art radiopharmaceutical…
-
Pharmaron Beijing to Establish Singapore JV Rxilient Biohub for CDMO Services
•
China-based Contract Development and Manufacturing Organization (CDMO) Pharmaron Beijing Co., Ltd (HKG: 3759, SHE: 300759) has announced plans to invest USD 10.5 million in establishing a joint venture (JV) named Rxilient Biohub Pte. Ltd. in Singapore. This strategic move marks Pharmaron’s expansion into the Southeast Asian market, aiming to provide…
-
Abbott Reports 8.7% Drop in Q3 2023 Global Sales, Hit by Lower SARS-CoV-2 Test Demand
•
Abbott (NYSE: ABT) published its Q3 2023 financial results this week, reporting a 8.7% year-on-year (YOY) decline in global sales on an organic basis to USD 29.9 billion over the first three quarters. The decrease was primarily attributed to significantly reduced demand for SARS-CoV-2 tests, which led to a 42.1%…
-
J&J Reports Strong Q3 2023 Sales Growth Amid Diverse Business Performance
•
Johnson & Johnson (J&J; NYSE: JNJ) has released its Q3 2023 report, revealing impressive global sales of USD 63.7 billion for the first nine months of the year. This marks a 7.5% year-on-year (YOY) expansion in operational terms, reflecting robust performance across both of the company’s main business segments. Segment…
-
Sirius Therapeutics Secures USD 60 Million in Series B Financing for siRNA Therapy Development
•
Sirius Therapeutics, a Shanghai-based developer of siRNA therapies, has successfully raised USD 60 million in a Series B financing round. This funding is specifically allocated for the clinical development of its siRNA therapy product pipelines and the advancement of next-generation nucleic acid molecular delivery technologies. The financing round was led…
-
EpimAb Biotherapeutics Licenses Bispecific Antibody Platform to Almirall
•
Shanghai-based EpimAb Biotherapeutics has entered into a strategic license agreement with Spanish pharmaceutical company Almirall for the development of bispecific antibodies (BsAbs) against up to three undisclosed target pairs. This partnership marks a significant step in leveraging EpimAb’s innovative Fabs-In-Tandem Immunoglobulin (FIT-Ig) platform to generate BsAbs, with Almirall securing exclusive…
-
Suzhou Inhal Pharma Secures Series A Funding for Expansion and Clinical Advances
•
Suzhou Inhal Pharma Co., Ltd, a China-based company dedicated to the research and development of inhalation formulations, inhalers, and filling equipment, has reportedly secured over RMB 50 million (USD 6.8 million) in a Series A financing round. The investment round was spearheaded by Shining Capital, marking a significant boost for…
-
Atom Bioscience Secures $82M Series D to Advance Gout Treatment ABP-671
•
China-based Atom Bioscience, known formally as Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd, has reportedly raised over RMB 600 million (USD 82 million) in a Series D financing round. This follows a GTJA Investment-led Series C financing round in January 2022, which raised RMB 300 million (USD 41 million). The…
-
Shanghai Pharma Health Commerce Secures $68M in Series C Funding Round
•
Shanghai Pharma Health Commerce Co., Ltd, a distinguished former subsidiary of China’s pharmaceutical giant Shanghai Pharmaceuticals Holding Co., Ltd (SHA: 601607), has reportedly secured RMB 500 million (USD 68 million) in a Series C financing round. This substantial investment underscores the company’s robust growth and potential within the healthcare sector.…
-
Novo Nordisk Reports 33% YOY Sales Increase, Boosts GLP-1 Drug Sales Forecast
•
Denmark-headquartered pharmaceutical giant Novo Nordisk (NYSE: NVO) provided a financial update last week, revealing a robust 33% year-on-year (YOY) increase in sales at constant exchange rates (CER) from Q1 to Q3 this year. Notably, Q3 alone saw a significant 38% YOY jump, indicating a strong market reception for the company’s…
-
Pfizer Adjusts 2023 Revenue Projections Amidst Decreased COVID-19 Solution Demand
•
Pharmaceutical giant Pfizer Inc. (NYSE: PFE) has revised its projected 2023 revenues downward, reflecting a decrease in demand for COVID-19 solutions. The new revenue projection falls between USD 58.0 billion and 61.0 billion, a significant adjustment from the previously anticipated range of USD 67.0 billion to 70.0 billion as reported…
-
Sino Biopharmaceutical Sells 84.2% Stake in Shanghai CP General Pharmaceutical
•
China-based biotech company Sino Biopharmaceutical Ltd (HKG: 1177) has announced the sale of an 84.2% stake in its former subsidiary, Shanghai CP General Pharmaceutical Co., Ltd. This strategic divestiture is expected to generate approximately RMB 290 million (USD 40 million) for the company. Focus on Core Competencies Amid Financial Losses…
-
Shanghai Shende Wuchuang Secures $28 Million in Series D Financing for Medical Device Innovation
•
Shanghai Shende Wuchuang Times Medical Technology Co., Ltd has reportedly secured nearly RMB 200 million (USD 28 million) in a Series D financing round, bringing the company’s total funding to RMB 400 million (USD 56 million). The investors in this round include Zhuji Huiri Yingtian Equity Investment and Hefei Industrial…
-
Hangzhou HealSun Biopharm Secures RMB 200 Million in Series B+ Financing
•
Hangzhou HealSun Biopharm Co., Ltd., a Chinese contract research organization (CRO) and contract development and manufacturing organization (CDMO) specializing in antibodies and recombinant proteins, has successfully raised nearly RMB 200 million (approximately USD 27.8 million) in a Series B+ financing round. The funding was led by China Medical System Holdings…
-
Cardinal Health Acquires MedAlliance for $1.135 Billion to Enhance Vascular Intervention Portfolio
•
US-based Cardinal Health (NYSE: CAH) has announced the acquisition of Swiss firm MedAlliance for a total consideration of USD 1.135 billion. This transaction includes a USD 35 million investment made in 2022, a USD 200 million upfront payment in 2023, and additional regulatory milestone payments totaling USD 125 million, along…
-
Triastek Inc. Secures $20.5 Million in Pre-Series C Financing for 3D Printing Pipeline
•
China-based Triastek Inc., a company at the forefront of pharmaceutical-focused 3D printing, has reportedly secured RMB 150 million (USD 20.5 million) in a pre-Series C financing round. The investment, led by Guoxin Investment, includes participation from Gold Mine Multi-Family Office and Zheng Xiaodong, chairman of Shanghai Tofflon Sci &Tech Co.,…
-
MitrAssist Lifesciences Secures $100 Million in Series C Financing for Cardiovascular Devices
•
MitrAssist Lifesciences Ltd, a Shanghai-based innovator in cardiovascular device manufacturing, has reportedly raised nearly USD 100 million in a Series C financing round. The funding was led by Centurium Capital and 6 Dimensions Capital, with contributions from Shanghai Jiading Industrial Development Group, Shanghai Jiajia Group, Hefei Haiheng Holdings, Hefei Industrial…
-
Hangzhou Qihan Biotechnology Secures Over $13.8 Million in Pre-Series B Financing
•
Hangzhou Qihan Biotechnology Co., Ltd, a leading xenotransplantation specialist based in China, has reportedly raised over RMB 100 million (USD 13.8 million) in a pre-Series B financing round. The funds will be allocated to support product iteration and global development initiatives over the next four years, marking a significant step…
-
Gurnet Point Capital and Novo Holdings Acquire Paratek Pharmaceuticals for $462 Million
•
Healthcare fund Gurnet Point Capital (GPC) and Novo Holdings, the controlling shareholder of Novo Nordisk (NYSE: NVO), have completed the acquisition of biopharmaceutical company Paratek Pharmaceuticals (NASDAQ: PRTK) this week. The acquisition solidifies the group’s position in the market and expands their portfolio with the addition of the antibiotic Nuzyra…
-
Lynk Pharmaceuticals Secures Series C2 Financing to Advance pipeline
•
Lynk Pharmaceuticals Co., Ltd, a China-based pharmaceutical company, has announced the successful completion of its Series C2 financing round. The round saw participation from the Shaoxing Binhai New Area Biomedical Industry Equity Investment Fund, managed by China Grand Prosperity Investment, Haibang Venture, and Howbuy Primary Fund, with existing shareholders New…
-
Tianjin Century Kangtai Biomedical Raises Hundreds of Millions in Series A+ and B Financings
•
Tianjin Century Kangtai Biomedical Engineering Co., Ltd, a China-based company, has reportedly secured hundreds of millions of renminbi through Series A+ and Series B financing rounds. The Series B round was led by SDIC, with participation from Efung Capital, Lake VC, Morning Spring Venture, and Jinju Capital. The funds raised…
-
Northeast Pharmaceutical Partners with Muscat Changming for Middle East Expansion
•
China-based Northeast Pharmaceutical Co., Ltd (SHE: 000597) has entered into an investment framework agreement with Muscat Changming Investments LLC, leveraging business development plans and market demand in Oman and the Middle East. Joint Venture Establishment and ObjectivesThe partnership aims to establish a joint venture (JV) in the Sultanate of Oman,…
-
BRIM Biotechnology Raises $45.8 Million in Premium Share Issue for Pipeline Expansion
•
Taiwan-based BRIM Biotechnology, Inc. (TPEx 6885), a biotechnology company specializing in the development of regenerative peptides for ophthalmology and degenerative joint diseases, has announced the successful issuance of 22,500 shares at a premium of USD 2.03, raising a total of USD 45.8 million. The rights issue was fully paid on…
-
Suzhou Acumen Biomedical Secures $13.8 Million in Series A+ Funding Round
•
China’s Suzhou Acumen Biomedical Technology Co., Ltd. has reportedly raised close to RMB 100 million (USD 13.8 million) in a Series A+ financing round. The round was led by Qiandao Investment Fund, with participation from Broad Resource Investment. The funds raised will be allocated towards the expansion of the company’s…
-
Sichuan Kelun Pharmaceutical Secures Exclusive Rights to TBM-001 for Bone Metastasis Diagnosis
•
Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422), through its innovative drug development subsidiary Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990), has entered into an exclusive licensing agreement with the Affiliated Hospital of Southwest Medical University. The agreement pertains to TBM-001, a radionuclide drug conjugate (RDC) designed for early diagnosis and…
-
Dialaibo Biotechnology Secures Series A Funding to Boost R&D and Manufacturing
•
China-based Dialaibo (Zhangjiagang) Biotechnology Co., Ltd has reportedly raised close to RMB 100 million (USD 13.7 million) in a Series A finance round. The round was led by Grand Yangtze Capital, with participation from Shulan Junjie Capital, Zhangjiagang Jinmao Venture Capital, Zhangjiagang Talent No.1 Fund, and Zhangjiagang Bonded Area Wisdom…
-
Canton Biologics Secures Over RMB 300 Million in Series C Financing for Expansion
•
Canton Biologics Co., Ltd, a Guangzhou-based Contract Development and Manufacturing Organization (CDMO) specializing in biologic drugs, has reportedly raised over RMB 300 million (USD 27.5 million) in a Series C financing round. The round was led by SDIC Venture Capital, with additional investments from Guangdong Technology Financial Group, Taipu Life…
-
Wecare Medical Secures Pre-Series A Funding to Advance Brain Health Technology
•
Hangzhou-based Wecare Medical, a developer of brain disease diagnosis, monitoring, and treatment products, has reportedly raised tens of millions of renminbi in a Pre-Series A financing round. The round was led by Noyu Capital, with the proceeds earmarked for accelerating the development of temporal interference-based non-invasive deep brain electrical stimulation…
-
Shanghai Haoyuan Chemexpress Aims to Raise RMB 1.16 Billion with Convertible Bonds
•
China-based Contract Development and Manufacturing Organization (CDMO) Shanghai Haoyuan Chemexpress Co., Ltd (SHA： 688131) has announced plans to raise up to RMB 1.16 billion (USD 160 million) through the issuance of an undisclosed amount of convertible bonds (CDs). This strategic financing move is expected to strengthen the company’s financial position…
-
GluBio Pharmaceutical Secures $22 Million in A+ Round Financing to Advance Protein Degradation Drugs
•
GluBio Pharmaceutical Co., Ltd., an emerging player in targeted protein degradation drug development, has announced the successful completion of a $22 million A+ round financing. Since its inception in March 2021, the company has raised nearly $90 million in total funding. This latest round was led by existing investor Qiming…
-
Med Vision Secures A+ Round Financing to Accelerate Digital Therapy Commercialization
•
Hangzhou-based Med Vision Technology Co., Ltd. has successfully completed an A+ round financing, raising several tens of millions of RMB. This round was led by Hangzhou Lingxin, with existing shareholder Mifang Health Fund participating. With this financing, Med Vision has cumulatively raised over 100 million RMB in its Series A…
-
Gritgen Therapeutics Secures Hundreds of Millions in A-Round Financing for Gene Therapy Pipeline
•
Gritgen Therapeutics, a leading gene therapy drug developer based in Suzhou, has announced the successful completion of a A-round financing round worth several hundred million yuan. The financing was led by Sequoia China, with participation from Sunlight Insurance, Qingsong Capital, and Beijing Life Science Park Venture Fund. Existing shareholders including…
-
Exegenesis Bio Secures Multi-Million Dollar Series B Financing for Gene Therapy Pipeline
•
Exegenesis Bio Inc., a leading gene therapy company, has successfully completed a Series B financing round, raising tens of millions of dollars. The round was led by Legend Capital, with Boyuan Capital, Taikang Capital, and previous investors Xianfeng Qiyun and Kaitong Capital participating. The funds raised will be directed towards…
-
Asymchem Laboratories Secures RMB 2.31 Billion Private Placement with Hill House Capital Subscription
•
Asymchem Laboratories (Tianjin) Co., Ltd, a renowned Contract Development and Manufacturing Organization (CDMO) based in China and listed on the SZSE under the ticker (002821), has unveiled a significant private placement initiative. The company will issue 18,700,000 A shares at a price of RMB 123.56 per share. Hill House Capital,…
-
LanssonPharm Secures Series A Funding to Accelerate CNS Drug Development
•
LanssonPharm, a company dedicated to the development of central nervous system (CNS) drugs, has announced the completion of a Series A funding round worth tens of millions of yuan. The financing was led by Yipu Capital, with follow-on investments from Qianrong Capital and existing shareholder Northern Light Venture Capital. This…
